<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles - Mochtar, MH - 2017 | Cochrane Library</title> <meta content="Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles - Mochtar, MH - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005070.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles - Mochtar, MH - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005070.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005070.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles" name="citation_title"/> <meta content="Monique H Mochtar" name="citation_author"/> <meta content="Academic Medical Center, University of Amsterdam" name="citation_author_institution"/> <meta content="M.H.Mochtar@amc.uva.nl" name="citation_author_email"/> <meta content="Nora A Danhof" name="citation_author"/> <meta content="Academic Medical Center, University of Amsterdam" name="citation_author_institution"/> <meta content="Reuben Olugbenga Ayeleke" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Fulco Van der Veen" name="citation_author"/> <meta content="Academic Medical Center, University of Amsterdam" name="citation_author_institution"/> <meta content="Madelon van Wely" name="citation_author"/> <meta content="Academic Medical Center, University of Amsterdam" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD005070.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/05/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005070.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005070.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005070.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abortion, Spontaneous [epidemiology]; Drug Therapy, Combination; Fertilization in Vitro [methods]; Follicle Stimulating Hormone [*administration &amp; dosage]; Live Birth [epidemiology]; Luteinizing Hormone [*administration &amp; dosage]; Ovarian Hyperstimulation Syndrome [chemically induced]; Ovulation Induction [*methods]; Pregnancy Rate; Randomized Controlled Trials as Topic; Recombinant Proteins [administration &amp; dosage]; Sperm Injections, Intracytoplasmic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005070.pub3&amp;doi=10.1002/14651858.CD005070.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005070\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005070\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005070.pub3",title:"Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles",firstPublishedDate:"May 24, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005070.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005070.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005070.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005070.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005070.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005070.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005070.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005070.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005070.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005070.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4569 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005070.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-sec-0102"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/appendices#CD005070-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/table_n/CD005070StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/table_n/CD005070StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information#CD005070-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Monique H Mochtar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information#CD005070-cr-0003">Nora A Danhof</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information#CD005070-cr-0004">Reuben Olugbenga Ayeleke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information#CD005070-cr-0005">Fulco Van der Veen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information#CD005070-cr-0006">Madelon van Wely</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information/en#CD005070-sec-0124">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 May 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005070.pub3">https://doi.org/10.1002/14651858.CD005070.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005070-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005070-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005070-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005070-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005070-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005070-abs-0001" lang="en"> <section id="CD005070-sec-0001"> <h3 class="title" id="CD005070-sec-0001">Background</h3> <p>One of the various ovarian stimulation regimens used for in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycles is the use of recombinant follicle‐stimulating hormone (rFSH) in combination with a gonadotrophin‐releasing hormone (GnRH) analogue. GnRH analogues prevent premature luteinizing hormone (LH) surges. Since they deprive the growing follicles of LH, the question arises as to whether supplementation with recombinant LH (rLH) would increase live birth rates. This is an updated Cochrane Review; the original version was published in 2007. </p> </section> <section id="CD005070-sec-0002"> <h3 class="title" id="CD005070-sec-0002">Objectives</h3> <p>To compare the effectiveness and safety of recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) for ovarian stimulation compared to rFSH alone in women undergoing in‐vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI). </p> </section> <section id="CD005070-sec-0003"> <h3 class="title" id="CD005070-sec-0003">Search methods</h3> <p>For this update we searched the following databases in June 2016: the Gynaecology and Fertility Group Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO and ongoing trials registers, and checked the references of retrieved articles. </p> </section> <section id="CD005070-sec-0004"> <h3 class="title" id="CD005070-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing rLH combined with rFSH versus rFSH alone in IVF/ISCI cycles. </p> </section> <section id="CD005070-sec-0005"> <h3 class="title" id="CD005070-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies, assessed risk of bias, and extracted data. We combined data to calculate odds ratios (ORs) and 95% confidence intervals (CIs). We assessed statistical heterogeneity using the I<sup>2</sup> statistic. We assessed the overall quality of the evidence for the main comparisons using GRADE methods. Our primary outcomes were live birth rate and incidence of ovarian hyperstimulation syndrome (OHSS). Secondary outcomes included ongoing pregnancy rate, miscarriage rate and cancellation rates (for poor response or imminent OHSS). </p> </section> <section id="CD005070-sec-0006"> <h3 class="title" id="CD005070-sec-0006">Main results</h3> <p>We included 36 RCTs (8125 women). The quality of the evidence ranged from very low to moderate. The main limitations were risk of bias (associated with poor reporting of methods) and imprecision. </p> <p>Live birth rates: There was insufficient evidence to determine whether there was a difference between rLH combined with rFSH versus rFSH alone in live birth rates (OR 1.32, 95% CI 0.85 to 2.06; n = 499; studies = 4; I<sup>2</sup> = 63%, very low‐quality evidence). The evidence suggests that if the live birth rate following treatment with rFSH alone is 17% it will be between 15% and 30% using rLH combined with rFSH. </p> <p>OHSS: There may be little or no difference between rLH combined with rFSH versus rFSH alone in OHSS rates (OR 0.38, 95% CI 0.14 to 1.01; n = 2178; studies = 6; I<sup>2</sup> = 10%, low‐quality evidence). The evidence suggests that if the rate of OHSS following treatment with rFSH alone is 1%, it will be between 0% and 1% using rLH combined with rFSH. </p> <p>Ongoing pregnancy rate: The use of rLH combined with rFSH probably improves ongoing pregnancy rates, compared to rFSH alone (OR 1.20, 95% CI 1.01 to 1.42; participants = 3129; studies = 19; I<sup>2</sup> = 2%, moderate‐quality evidence). The evidence suggests that if the ongoing pregnancy rate following treatment with rFSH alone is 21%, it will be between 21% and 27% using rLH combined with rFSH. </p> <p>Miscarriage rate: The use of rLH combined with rFSH probably makes little or no difference to miscarriage rates, compared to rFSH alone (OR 0.93, 95% CI 0.63 to 1.36; n = 1711; studies = 13; I<sup>2</sup> = 0%, moderate‐quality evidence). The evidence suggests that if the miscarriage rate following treatment with rFSH alone is 7%, the miscarriage rate following treatment with rLH combined with rFSH will be between 4% and 9%. </p> <p>Cancellation rates: There may be little or no difference between rLH combined with rFSH versus rFSH alone in rates of cancellation due to low response (OR 0.77, 95% CI 0.54 to 1.10; n = 2251; studies = 11; I<sup>2</sup> = 16%, low quality evidence). The evidence suggests that if the risk of cancellation due to low response following treatment with rFSH alone is 7%, it will be between 4% and 7% using rLH combined with rFSH. </p> <p>We are uncertain whether use of rLH combined with rFSH improves rates of cancellation due to imminent OHSS compared to rFSH alone. Use of a fixed effect model suggested a benefit in the combination group (OR 0.60, 95% CI 0.40 to 0.89; n = 2976; studies = 8; I<sup>2</sup> = 60%, very low quality evidence) but use of a random effects model did not support the conclusion that there was a difference between the groups (OR 0.82, 95% CI 0.34 to 1.97). </p> </section> <section id="CD005070-sec-0007"> <h3 class="title" id="CD005070-sec-0007">Authors' conclusions</h3> <p>We found no clear evidence of a difference between rLH combined with rFSH and rFSH alone in rates of live birth or OHSS. The evidence for these comparisons was of very low‐quality for live birth and low quality for OHSS. We found moderate quality evidence that the use of rLH combined with rFSH may lead to more ongoing pregnancies than rFSH alone. There was also moderate‐quality evidence suggesting little or no difference between the groups in rates of miscarriage. There was no clear evidence of a difference between the groups in rates of cancellation due to low response or imminent OHSS, but the evidence for these outcomes was of low or very low quality. </p> <p>We conclude that the evidence is insufficient to encourage or discourage stimulation regimens that include rLH combined with rFSH in IVF/ICSI cycles. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005070-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005070-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005070-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005070-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005070-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD005070-abs-0005">Português</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005070-abs-0004" lang="en"> <h3>Recombinant luteinizing hormone (rLH) and recombinant follicle‐stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles </h3> <p><b>Review question</b> </p> <p>What is the effectiveness and safety of a combination of recombinant luteinizing hormone (rLH) and recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in women undergoing in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI)? </p> <p><b>Background</b> </p> <p>In natural ovarian cycles, luteinizing hormone and follicle‐stimulating hormone (FSH) are necessary for the maturation of ovarian follicles. One of the various stimulation regimens in IVF or ICSI cycles is ovarian stimulation with rFSH in combination with a gonadotrophin‐releasing hormone (GnRH) analogue. GnRH analogues prevent premature luteinizing hormone surges. Since they deprive the growing follicles of luteinizing hormone, the question arises as to whether supplementation with recombinant luteinizing hormone (rLH) would increase live birth rates. </p> <p><b>Study characteristics</b> </p> <p>We found 36 randomized controlled trials comparing rLH combined with rFSH versus rFSH alone among 8125 women undergoing IVF/ICSI. This is an update of a previous Cochrane Review, first published in 2007. The evidence is current to June 2016. Only seven of the 36 studies clearly stated that they were funded by government or research institutes. Six were funded by pharmaceutical companies and the rest did not state their source of funding. </p> <p><b>Key results</b> </p> <p>We found no clear evidence of a difference between rLH combined with rFSH and rFSH alone in rates of live birth or OHSS. The evidence for these comparisons was of very low‐quality for live birth and low quality for OHSS. We found moderate quality evidence that the use of rLH combined with rFSH may lead to more ongoing pregnancies than rFSH alone. There was also moderate‐quality evidence suggesting little or no difference between the groups in rates of miscarriage. There was no clear evidence of a difference between the groups in rates of cancellation due to low response or imminent OHSS, but the evidence for these outcomes was of low or very low quality. </p> <p>We conclude that the evidence is too limited to encourage or discourage stimulation regimens that include rLH combined with rFSH in IVF/ICSI cycles. </p> <p><b>Quality of evidence</b> </p> <p>The quality of the evidence ranged from very low to moderate. The main limitations were risk of bias (associated with poor reporting of methods) and imprecision. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005070-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005070-sec-0108"></div> <h3 class="title" id="CD005070-sec-0109">Implications for practice</h3> <section id="CD005070-sec-0109"> <p>We found no clear evidence of a difference between rLH combined with rFSH and rFSH alone in rates of live birth or OHSS. The evidence for these comparisons was of very low‐quality for live birth and low quality for OHSS. We found moderate quality evidence that the use of rLH combined with rFSH may lead to more ongoing pregnancies than rFSH alone. There was also moderate‐quality evidence suggesting little or no difference between the groups in rates of miscarriage. There was no clear evidence of a difference between the groups in rates of cancellation due to low response or due to imminent OHSS, but the evidence for these outcomes was of low or very low quality. </p> <p>We conclude that the evidence is too limited to encourage or discourage stimulation regimens that include rLH combined with rFSH in IVF/ICSI cycles. </p> </section> <h3 class="title" id="CD005070-sec-0110">Implications for research</h3> <section id="CD005070-sec-0110"> <p>We suggest a systematic review and meta‐analysis addressing the head‐to‐head comparison of whether HP‐HMG or rLH combined with rFSH is the most effective and safe in GnRH analogue downregulated IVF/ICSI cycles. We suggest a cost‐effectiveness analysis on the combination of rLH and rFSH compared to rFSH alone in GnRH agonist downregulated IVF/ICSI cycles. In addition, we suggest an individual patient data analysis on the effectiveness of rLH combined with rFSH in women with poor ovarian response and in women of advanced age. All studies should clearly report their funding source. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005070-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005070-sec-0022"></div> <div class="table" id="CD005070-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) versus rFSH alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women undergoing ovarian stimulation in IVF or ICSI treatment cycles<br/> <b>Settings:</b> assisted reproduction clinics<br/> <b>Intervention:</b> rLH combined with rFSH<br/> <b>Comparison:</b> rFSH alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> rFSH alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> rLH plus rFSH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>173 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> <br/> (151 to 302) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b> <br/> (0.85 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS incidence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (2 to 13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.38</b> <br/> (0.14 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2178<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ongoing pregnancy rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>206 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> <br/> (207 to 269) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.20</b> <br/> (1.01 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3129<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Miscarriage rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>65 per 1000</b> </p> <p>(45 to 93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.93</b> </p> <p>(0.63 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1711</p> <p>(13 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cancellation rate for low response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>52 per 1000</p> <p>(37 to 73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.77</p> <p>(0.54 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2251</p> <p>(11 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cancellation rate for imminent OHSS</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>27 per 1000</p> <p>(18 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.60</p> <p>(0.40 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2976</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>very low</b><sup>2,4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IVF</b> : in‐vitro fertilisation<b>; OHSS</b> : ovarian hyperstimulation syndrome; <b>OR:</b> Odds ratio; <b>rFSH:</b> recombinant follicle‐stimulating hormone;<b>rLH:</b> recombinant luteinizing hormone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High‐quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate‐quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low‐quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low‐quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to imprecision: effect estimate with wide confidence interval (wider than the interval 0.75 to 1.25) or low event rate.<br/> <sup>2</sup> Downgraded one level due to the presence of serious risk of bias in certain domains such as random sequence generation and allocation concealment.<br/> <sup>3</sup>Downgraded two levels due to very serious imprecision with wide confidence interval (wider than the interval 0.75 to 1.25) and very low event rate. </p> <p><sup>4</sup> Downgraded one level due to inconsistency (I<sup>2</sup> &gt;50%) </p> <p><sup>5</sup>Downgraded one level due to imprecision: findings are sensitive to choice of statistical model and are not statistically significant with use of a random effects model (OR 0.82, 95% CI 0.34 to 1.97) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005070-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005070-sec-0023"></div> <section id="CD005070-sec-0024"> <h3 class="title" id="CD005070-sec-0024">Description of the condition</h3> <p>About 15% of couples fail to achieve conception after a year of unprotected intercourse (<a href="./references#CD005070-bbs2-0070" title="TeVeldeER , EijkemansR , HabbemaHD . Variation in couple fecundity and time to pregnancy, an essential concept in human reproduction. Lancet2000;355(9219):1928‐9. ">Te Velde 2000</a>). Such couples may choose to undergo an assisted reproductive technology procedure such as in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). </p> </section> <section id="CD005070-sec-0025"> <h3 class="title" id="CD005070-sec-0025">Description of the intervention</h3> <p>One of the various stimulation regimens in IVF or ICSI consists of daily administration of subcutaneous injections of recombinant follicle‐stimulating hormone (rFSH) to induce multiple follicle growth in the ovaries. An integral part of this stimulation regimen is daily subcutaneous injections of a gonadotrophin‐releasing hormone (GnRH) analogue to prevent a premature luteinizing hormone (LH) surge. Two kinds of GnRH analogues are available, a GnRH agonist or a GnRH antagonist. </p> <p>The intervention to be compared with this stimulation regimen is the addition of daily subcutaneous injections of recombinant luteinizing hormone (rLH) to rFSH. </p> </section> <section id="CD005070-sec-0026"> <h3 class="title" id="CD005070-sec-0026">How the intervention might work</h3> <p>Growing follicles become increasingly sensitive to, and ultimately dependent on, the presence of both luteinizing hormone (LH) and follicle‐stimulating hormone (FSH) for their development. As described in the classic 'two cell ‐ two gonadotrophin' theory, LH is needed to provide the granulosa cells with androgen precursors for estradiol biosynthesis by FSH (<a href="./references#CD005070-bbs2-0068" title="ShortRV . Steroids in the follicular fluid and the corpus luteum of the mare. A 'two‐cell type' theory of ovarian steroid synthesis. Journal of Endocrinology1962;24:59‐63. ">Short 1962</a>). LH is also needed for the resumption of meiosis and for progesterone production after ovulation to sustain the endometrium. The profound pituitary downregulation with GnRH agonists blocks the output of LH for at least 10 days after cessation of the GnRH agonist and deprives the growing follicles completely of LH stimulation during the entire stimulation phase (<a href="./references#CD005070-bbs2-0059" title="BroekmansF , BernardusR , BerkhoutG , SchoenmakerJ . Pituitary and ovarian suppression after early follicular and mid‐luteal administration of LHRH agonist in a depot formulation: decapeptyl CR. Gynecoligal Endocrinology1992;6:153‐61. ">Broekmans 1992</a>; <a href="./references#CD005070-bbs2-0069" title="SmitzJ , DevroeyP , CamusM , DeschachtJ , KhanI , StaessenC , et al. The luteal phase and early pregnancy after combined GnRH‐agonist/HMG treatment for superovulation in IVF or GIFT. Human Reproduction1988;3(5):585‐90. ">Smitz 1988</a>), while during downregulation with a GnRH antagonist, the output of LH remains present during the stimulation phase and the blockage of LH takes place periovulatory for only three to five days. </p> <p>In view of the endocrinology of the normal menstrual cycle and the negative impact of the pituitary downregulation on folliculogenesis, the intervention of ovarian stimulation with rLH combined with rFSH in downregulated IVF/ICSI cycles may have beneficial effects for growing follicles and may lead to better pregnancy outcomes compared to rFSH alone. A meta‐analysis showed that urinary human menopausal gonadotrophins (HMG), a combination of FSH and hCG in a 1:1 ratio, leads to significantly higher rates in live birth and ongoing pregnancy than rFSH in IVF or ICSI cycles, emphasising a possible role for hCG/LH (<a href="./references#CD005070-bbs2-0072" title="vanWelyM , KwanI , BurtAL , ThomasJ , VailA , Van derVeenF , et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2] ">van Wely 2011</a>). </p> </section> <section id="CD005070-sec-0027"> <h3 class="title" id="CD005070-sec-0027">Why it is important to do this review</h3> <p>This is an update of a review first published in 2007 (<a href="./references#CD005070-bbs2-0075" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM . Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2] ">Mochtar 2007</a>). International guidelines do not specify a particular stimulation regimen for IVF or ICSI as regimen of first choice (European Society of Human Reproduction and Embryology (ESHRE), American Society for Reproductive Medicine (ASRM), National Institute for Health and Care Excellence (NICE), Nederlandse Vereniging voor Obstetrie en Gynaecologie (NVOG)). Since 2006 a substantial amount of new data on rLH combined with rFSH in comparison to rFSH became available. The continuing uncertainty regarding a role for rLH in ovarian stimulation is still ongoing due to conflicting results from a large number of trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005070-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005070-sec-0028"></div> <p>To compare the effectiveness and safety of recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) for ovarian stimulation compared to rFSH alone in women undergoing in‐vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005070-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005070-sec-0029"></div> <section id="CD005070-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005070-sec-0031"> <h4 class="title">Types of studies</h4> <p>Truly randomized controlled studies (RCTs) were eligible for inclusion. We excluded pseudo‐randomised studies as they are associated with a high risk of bias (<a href="./references#CD005070-bbs2-0071" title="VailA , GardenerE . Common statistical errors in the design and analysis of subfertility trials. Human Reproduction2003;18:1000‐4. ">Vail 2003</a>). </p> </section> <section id="CD005070-sec-0032"> <h4 class="title">Types of participants</h4> <p>Women undergoing in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). </p> </section> <section id="CD005070-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We compared recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) to rFSH alone as stimulation protocols in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) followed by embryo transfer. </p> </section> <section id="CD005070-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD005070-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>1. Live birth rate; defined as delivery of a live foetus after 20 completed weeks of gestation. </p> <p>2. Primary safety outcome: incidence of ovarian hyperstimulation syndrome (mild, moderate, or severe). </p> </section> <section id="CD005070-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>3. Ongoing pregnancy rate; defined as foetal heartbeat at 12 weeks gestation.</p> <p>4. Clinical pregnancy rate; defined as gestational sac at ultrasound, with or without foetal heartbeat, any time before 12 weeks gestation. </p> <p>5. Miscarriage rate; defined as any pregnancy loss before 20 weeks of gestation.</p> <p>6. Cancellation rate due to low response.</p> <p>7. Cancellation rate due to imminent ovarian hyperstimulation syndrome.</p> </section> </section> </section> <section id="CD005070-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant studies describing RCTs of women undergoing ovarian stimulation with recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) and rFSH alone for IVF or ICSI, without language restriction. The original search was performed in 2006 and updated in 2010 and 2012. In the latest update, we searched relevant studies from 2012 up to 9 June 2016. </p> <p>We carried out all searches in consultation with the Gynaecology and Fertility Group (formerly Menstrual Disorders and Subfertility Group (MDSG)) Information Specialist. </p> <section id="CD005070-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases, trial registers and websites.</p> <p>The Gynaecology and Fertility (formerly Menstrual Disorders and Subfertility) Group Specialised Register of Controlled Trials (from 2010 to June 2016) (<a href="./appendices#CD005070-sec-0114">Appendix 1</a>); the Cochrane Central Register of Studies Online (CRSO) (from 2012 to June 2016) (<a href="./appendices#CD005070-sec-0115">Appendix 2</a>); MEDLINE (from 2012 to June 2016) (<a href="./appendices#CD005070-sec-0116">Appendix 3</a>); Embase (from 2012 to June 2016) (<a href="./appendices#CD005070-sec-0117">Appendix 4</a>); and PsycINFO (from 2012 to June 2016) (<a href="./appendices#CD005070-sec-0118">Appendix 5</a>). The MEDLINE search was combined with the Cochrane highly sensitive search strategy for identifying randomized trials, which appears in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD005070-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. [www.cochrane‐handbook.org.] ">Higgins 2011</a>). The Embase, PsycINFO and CINAHL searches were combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="http://www.sign.ac.uk/methodology/filters.html#random" target="_blank">www.sign.ac.uk/methodology/filters</a>). </p> <p>Other electronic sources of trials included:</p> <p> <ul id="CD005070-list-0001"> <li> <p>trial registers for ongoing and registered trials;</p> </li> <li> <p><a href="http://www.clinicaltrials.gov" target="_blank">www.ClinicalTrials.gov</a> (a service of the US National Institutes of Health) (up to June 2016); </p> </li> <li> <p><a href="http://www.who.int/trialsearch/Default.aspx" target="_blank">www.who.int/trialsearch</a> (The World Health Organization International Trials Registry Platform search portal); (up to June 2016) </p> </li> <li> <p>DARE (Database of Abstracts of Reviews of Effects) on the Cochrane Library at <a href="http://onlinelibrary.wiley.com/o/cochrane/cochrane_cldare_articles_fs.html" target="_blank">onlinelibrary.wiley.com</a> (for reference lists from relevant non‐Cochrane reviews) (up to June 2016); </p> </li> <li> <p>the Web of Knowledge (<a href="http://wokinfo.com/" target="_blank">wokinfo.com</a>) (another source of trials and conference abstracts) (June 2016); </p> </li> <li> <p>OpenGrey ‐ (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu</a>) for unpublished literature from Europe (up to June 2016); </p> </li> <li> <p>LILACS database (<a href="http://regional.bvsalud.org/php/index.php?lang=en" target="_blank">regional.bvsalud.org</a>) (for trials from the Portuguese and Spanish speaking world) (up to June 2016); </p> </li> <li> <p>PubMed and Google Scholar (for recent trials not yet indexed in MEDLINE) (up to June 2016). </p> </li> </ul> </p> </section> <section id="CD005070-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists of articles retrieved by the search. We also handsearched relevant journals and conference abstracts that are not covered in the Gynaecology and Fertility Group Register, in liaison with the Information Specialist. </p> </section> </section> <section id="CD005070-sec-0040"> <h3 class="title" id="CD005070-sec-0040">Data collection and analysis</h3> <section id="CD005070-sec-0041"> <h4 class="title">Selection of studies</h4> <p>After an initial screen of titles and abstracts retrieved by the search, we retrieved the full‐text of all potentially eligible studies. Two review authors (ND and RA) independently examined these full‐text articles for compliance with the inclusion criteria and selected studies eligible for inclusion in the review. Disagreements as to study eligibility were resolved by discussion with a third review author (MM). We documented the selection process with a PRISMA flow chart (<a href="./references#CD005070-bbs2-0065" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. BMJ2009;339:2535. ">Moher 2009</a>; <a href="#CD005070-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD005070-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005070-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD005070-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (ND and RA) independently extracted date from eligible studies using forms designed according to Cochrane guidelines. We resolved any disagreements by discussion or by a third review author (MM). We extracted study characteristics and have presented outcome data from the included studies in the <a href="./references#CD005070-sec-0130" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD005070-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (ND and RA) independently assessed the included studies for risk of bias using the 'Risk of bias' assessment tool of Cochrane (<a href="./references#CD005070-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. [www.cochrane‐handbook.org.] ">Higgins 2011</a>). Disagreements were resolved by discussion or by a third review author (MM). We assessed selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition (incomplete outcome data); reporting (selective reporting); and other bias, such as significant differences in demographic characteristics between treatment groups at baseline. We described all judgements and presented the conclusions in the 'Risk of bias' table. </p> <section id="CD005070-sec-0044"> <h5 class="title">(1) Random sequence generation</h5> <p>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD005070-list-0002"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD005070-sec-0045"> <h5 class="title">(2) Allocation concealment</h5> <p>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD005070-list-0003"> <li> <p>low risk of bias (e.g. web or telephone randomization; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open list of random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> <section id="CD005070-sec-0046"> <h6 class="title">(3.1) Blinding of participants and personnel</h6> <p>No blinding is unlikely to introduce bias, so we assessed the methods at low risk of bias. </p> </section> <section id="CD005070-sec-0047"> <h6 class="title">(3.2) Blinding of outcome assessment</h6> <p>No blinding is unlikely to introduce bias, so we assessed the methods at low risk of bias. </p> </section> </section> <section id="CD005070-sec-0048"> <h5 class="title">(4) Incomplete outcome data</h5> <p>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total number of randomized participants), reasons for attrition or exclusion, where reported, and whether missing data were balanced across groups or were related to outcomes. </p> <p>We assessed methods as:</p> <p> <ul id="CD005070-list-0004"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure from intervention received from that assigned at randomization); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD005070-sec-0049"> <h5 class="title">(5) Selective reporting</h5> <p>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD005070-list-0005"> <li> <p>low risk of bias, where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review have been reported; </p> </li> <li> <p>high risk of bias, where not all the study’s prespecified outcomes were reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so cannot be used; failure to include results of a key outcome that would have been expected to have been reported; </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD005070-sec-0050"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> </section> </section> <section id="CD005070-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We performed statistical analyses in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005070-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. [www.cochrane‐handbook.org.] ">Higgins 2011</a>). We reported only dichotomous outcomes and for such outcomes; we used the numbers of events in the control and intervention groups of each study to calculate Mantel‐Haenszel odds ratios (ORs). We presented 95% confidence intervals (CIs) for all outcomes and we used the Review Manager software for statistical analysis (<a href="./references#CD005070-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For reporting purposes, we translated primary outcomes to absolute risks. </p> </section> <section id="CD005070-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was ‘per woman randomized’.</p> </section> <section id="CD005070-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We analyzed the data on an intention‐to‐treat basis, as far as possible, and we made attempts to obtain missing data from the original trialists. If data were not obtainable from the trial authors, we assumed that live births had not occurred. For other outcomes, we analyzed only the available data. </p> </section> <section id="CD005070-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by the measure of the I<sup>2</sup> statistic. An I<sup>2</sup> measurement greater than 50% was taken to indicate substantial heterogeneity (<a href="./references#CD005070-bbs2-0062" title="HigginsJP , TompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>; <a href="./references#CD005070-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. [www.cochrane‐handbook.org.] ">Higgins 2011</a>). </p> </section> <section id="CD005070-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We aimed to minimise the impact of reporting biases by ensuring a comprehensive search for eligible studies, while being alert to duplication of data. If there were 10 or more studies in an analysis, we used a funnel plot to explore the possibility of small study effects, since there is a tendency for estimates of the intervention effect to be more beneficial in smaller studies. </p> </section> <section id="CD005070-sec-0056"> <h4 class="title">Data synthesis</h4> <p>If studies were sufficiently similar, we combined the data using a fixed‐effect model.</p> </section> <section id="CD005070-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where there were sufficient data, we performed subgroup analyses for the following variables, for live birth, ovarian hyperstimulation syndrome, and ongoing pregnancy. </p> <p> <ul id="CD005070-list-0006"> <li> <p>Downregulating agent used for oocyte maturation GnRH agonist, or GnRH antagonist.</p> </li> </ul> <ul id="CD005070-list-0007"> <li> <p>Poor ovarian response, defined according to the Bologna criteria (<a href="./references#CD005070-bbs2-0060" title="FerrarettiAP , LaMarcaA , FauserBC , TarlatzisB , NargundG , GianaroliL , ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction2011;26(7):1616‐24. ">Ferraretti 2011</a>). </p> </li> </ul> <ul id="CD005070-list-0008"> <li> <p>Women of advanced age, defined as above 35 years of age.</p> </li> </ul> </p> <p>Where we detected substantial heterogeneity, we explored possible explanations in sensitivity analyses. We took any statistical heterogeneity into account when interpreting the results, especially where there was any variation in the direction of effect. </p> </section> <section id="CD005070-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>Where we identified substantial heterogeneity, we conducted sensitivity analyses. The analyses included the use of a random‐effects model instead of a fixed‐effect model and the use of risk ratios (RRs) rather than ORs. </p> <section id="CD005070-sec-0059"> <h5 class="title">Overall quality of the body of evidence: 'Summary of findings' table</h5> <p>We prepared a 'Summary of findings' table using GRADEpro GDT (<a href="./references#CD005070-bbs2-0061" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed prior to 12 November 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). This table evaluates the overall quality of the body of evidence for all review outcomes (<a href="./full#CD005070-tbl-0001">summary of findings Table for the main comparison</a>). We assessed the quality of the evidence using GRADE criteria (<a href="./references#CD005070-bbs2-0058" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>): risk of bias, consistency of effect, imprecision, indirectness, and publication bias. Two review authors working independently, made judgements about evidence quality (high, moderate, low or very low), with disagreements resolved by discussion. We justified, documented, and incorporated judgements into the reporting of results for each outcome. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005070-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005070-sec-0060"></div> <section id="CD005070-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD005070-sec-0062"> <h4 class="title">Results of the search</h4> <p>For the 2017 update, we identified 496 records. We retrieved 15 potentially eligible full‐text articles. Twelve studies met our inclusion criteria (these were in addition to the 24 studies included in the original review in 2007). We excluded three studies because they did not make the comparison of interest (<a href="./references#CD005070-bbs2-0045" title="Fei YangD , Jia YinL . Different LH add‐back and luteal phase supplement influence clinical outcome in GnRH antagonist protocol‐a prospective RCT study in fresh and frozen transfer cycles. Fertility and Sterility2013;100(3):S270. ">Fei Yang 2013</a>; <a href="./references#CD005070-bbs2-0046" title="FerminA , CrisolL , ExpositoA , PrietoB , MendozaR , MatorrasR . Influence of the fsh/lh ratio in ovarian stimulation in ivf results in women aged over 35 years: a randomized study. Human Reproduction2013;28:i311‐56. ">Fermin 2013</a>) or were not randomized (<a href="./references#CD005070-bbs2-0038" title="BarberiM , ErminiB , MorelliMB , ErminiM , CecconiS , CanipariR . Follicular fluid hormonal profile and cumulus cell gene expression in controlled ovarian hyperstimulation with recombinant FSH: Effects of recombinant LH administration. Journal of Assisted Reproduction and Genetics2012;29(12):1381‐91. ">Barberi 2012</a>). See <a href="./references#CD005070-sec-0130" title="">Characteristics of included studies</a>; <a href="./references#CD005070-sec-0131" title="">Characteristics of excluded studies</a>. </p> <p>The screening and selection process is presented in a PRISMA flow chart (<a href="./references#CD005070-bbs2-0065" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. BMJ2009;339:2535. ">Moher 2009</a>; <a href="#CD005070-fig-0001">Figure 1</a>). </p> </section> <section id="CD005070-sec-0063"> <h4 class="title">Included studies</h4> <section id="CD005070-sec-0064"> <h5 class="title">Study design and setting</h5> <p>We included a total of 36 RCTs in this update, of which 20 were single‐centred (<a href="./references#CD005070-bbs2-0001" title="AbdelmassihV , SalgueiroR , AbdelmassihC , CarizzaC . Less miscarriage rate using LH (rLH) in GnRH agonists long protocols. Twenty‐Second Annual Meeting of the European Society of Human Reproduction and Embryology; 2006 June 18‐21. Prague: ESHRE, 2006. ">Abdelmassih 2006</a>; <a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>; <a href="./references#CD005070-bbs2-0003" title="BalaschJ , CreusM , FabreguesF , CivicoS , CarmonaF , PuertoB , et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle‐stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary‐suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics2001;18(5):250‐6. ">Balasch 2001</a>; <a href="./references#CD005070-bbs2-0004" title="BarrenetxeaG , AgirregoikaJA , JimenezMR , Lopez de LarruzeaA , GanzabalT , CarboneroK . Ovarian response and pregnancy outcome in poor‐responder women: a randomised controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertility and Sterility2008;89(3):546‐53. ">Barrenetxea 2008</a>; <a href="./references#CD005070-bbs2-0005" title="BerkkanogluM , IsikogluM , AydinD , OzgurK . Clinical effects of ovulation induction with recombinant follicle‐stimulating hormone supplemented with recombinant luteinizing hormone or low‐dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertilility and Sterility2007;88(3):665‐9. ">Berkkanoglu 2007</a>; <a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0008" title="DemirolA , GurganT , GirginB . Supplementation of rec‐LH for poor responder patients. Abstracts of the 21st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2005 June 19‐22; Copenhagen. 2005:i74. ">Demirol 2005</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0014" title="Fernández RamírezMJ , MonzóA , García‐GimenoT , RubioJM , MontañanaV , DuqueC . Role of LH administration during the follicular phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF [Papel de la administracion de LH en el curso de la fase folicular en mujeres con riesgo de pobre respuesta en ciclos de estimulacion con FSH y cetrorelix para FIV]. Revista Iberoamericana de Fertilidad y Reproduccion Humana2006;23(5):281‐90. ">Fernandez‐Ramirez 2006</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0016" title="FerrarettiAP , GianaroliL , MotrenkoT , FelicianiE , TabanelliC , MagliMC . LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172] ">Ferraretti 2014</a>; <a href="./references#CD005070-bbs2-0017" title="GriesingerG , Schultze‐MosgauA , DafopoulosK , SchroederA , SchroerA , vonOtteS , et al. Recombinant luteinizing hormone supplementation to recombinant follicle‐stimulating hormone induced ovarian hyperstimulation in the GnRH‐antagonist multiple‐dose protocol. Human Reproduction2005;20(5):1200‐6. ">Griesinger 2005</a>; <a href="./references#CD005070-bbs2-0018" title="HumaidanP , BungumM , BungumL , Yding AndersenC . Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down‐regulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedine2004;8(6):635‐43. ">Humaidan 2004</a>; <a href="./references#CD005070-bbs2-0020" title="KovacsP , KovatsT , KaaliSG . Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertility and Sterility2010;93(2):475‐9. ">Kovacs 2010</a>; <a href="./references#CD005070-bbs2-0021" title="Levi‐SettiPE , CavagnaM , BullettiC . Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of rFSH alone and in combination with rLH. European Journal of Obstetrics and Gynecology and Reproductive Biology2006;126:212‐16. ">Levi‐Setti 2006</a>; <a href="./references#CD005070-bbs2-0022" title="LisiF , RinaldiL , FishelS , CasertaD , LisiR , CampbellA . Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertility and Sterility2005;83(2):309‐15. ">Lisi 2005</a>; <a href="./references#CD005070-bbs2-0023" title="LisiF , CasertaD , MontaninoM , BerlinghieriV , BielliW , CarfagnaP , et al. Recombinant luteinizing hormone priming in multiple follicular stimulation for in‐vitro fertilization downregulated patients. Gynecological Endocrinology2012;28(9):674‐7. [DOI: 10.3109/09513590.2011.652716] ">Lisi 2012</a>; <a href="./references#CD005070-bbs2-0025" title="MatorrasR , PrietoB , ExpositoA , MendozaR , CrisolL , HerranzP , et al. Mid‐follicular LH supplementation in women aged 35‐39 years undergoing ICSI cycles: a randomized controlled study. Reproductive Biomedicine Online2009;19(6):879‐87. ">Matorras 2009</a>; <a href="./references#CD005070-bbs2-0031" title="RaziMH , MohseniF , Dehghani FirouzabadiR , JanatiS , YariN , EtebaryS . Results from adding recombinant LH for assisted reproductive technology treatment: A randomized control trial. Iranian Journal of Reproductive Medicine2014;12(2):111‐6. ">Razi 2014</a>; <a href="./references#CD005070-bbs2-0032" title="RuvoloG , BoscoL , PaneA , MoriciG , CittadiniE , RoccheriMC . Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertility and Sterility2007;87(3):542‐6. ">Ruvolo 2007</a>), and seven were multicentred (<a href="./references#CD005070-bbs2-0007" title="CasertaD , LisiF , MarciR , CiardoF , FaziA , LisiR , et al. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?. Gynecological Endocrinology2011;27:862‐6. ">Caserta 2011</a>; <a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>; <a href="./references#CD005070-bbs2-0034" title="Van DerHouwenL , KonigTE , OverbeekA , HendriksML , BeemsterboerSN , KuchenbeckerWK , et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction2011; Vol. 26:i314‐5. ">Van der Houwen 2011</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0024" title="MarrsR , MeldrumD , MuasherS , SchoolcraftW , WerlinL , KellyE . Randomized trial to compare the effect of recombinant FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive Biomedicine Online2003;8(2):175‐82. ">Marrs 2003</a>; <a href="./references#CD005070-bbs2-0029" title="Nyboe AndersenA , HumaidanP , FriedG , HauskenJ , AntilaL , BangsbøllS , et al. Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre,prospective, randomized, controlled trial. Human Reproduction2008;23(2):427‐34. ">Nyboe Andersen 2008</a>). In the remaining nine studies this was not reported (<a href="./references#CD005070-bbs2-0010" title="DravidRM , ChimoteBN , ChimoteAN , ChimoteNN , ChimoteNM . Supplementation of recombinant LH to poor responders in mid‐follicular phase along with recombinant FSH results in better blastocyst formation and implantation rate in antagonist IVF cycles. 31st European Society of Human Reproduction and Embryology (ESHRE); 2015 June 14‐17; Lisbon. 2015:165. ">Dravid 2015</a>; <a href="./references#CD005070-bbs2-0011" title="EvangelioPM , BuendichoIE , YesteAM , GustemMRB , EgeaIB , HernandezNC . Randomized prospective study on the effect of the addition of the effect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response. Revista Iberoamericana de Fertilidad y Reproduccion Humana2011;28(3):3. ">Evangelio 2011</a>; <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0026" title="MohseniF , Dehgani FirouzabadiR , YariN , EtebaryS . Results of adding recombinant LH in normoresponder patients for assisted reproductive technology treatment: a prospective randomized control trial. International Journal of Fertility and Sterility2013;7:112. ">Mohseni 2013</a>; <a href="./references#CD005070-bbs2-0028" title="NazzaroA , SalemoA . Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH‐antagonist protocol improves implantation and pregnancy rates. Fertility and Sterility2012;98(3):S280. ">Nazzaro 2012</a>; <a href="./references#CD005070-bbs2-0030" title="PezzutoA , FerrariB , CoppolaF , NardelliGB . LH supplementation in down‐regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecological Endocrinology2010;26(2):118‐24. ">Pezzuto 2010</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>; <a href="./references#CD005070-bbs2-0036" title="YounisJS , IzhakiI , Ben‐AmiM . The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF‐ET: A prospective randomized controlled study. Fertility and Sterility2014;102(3):e23. ">Younis 2014</a>). </p> </section> <section id="CD005070-sec-0065"> <h5 class="title">Participants</h5> <p>We included a total of 8125 women undergoing in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) in these studies. Their mean age across studies ranged from 28 to 41 years. </p> <p>Eight studies included poor responders (<a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>; <a href="./references#CD005070-bbs2-0008" title="DemirolA , GurganT , GirginB . Supplementation of rec‐LH for poor responder patients. Abstracts of the 21st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2005 June 19‐22; Copenhagen. 2005:i74. ">Demirol 2005</a>; <a href="./references#CD005070-bbs2-0010" title="DravidRM , ChimoteBN , ChimoteAN , ChimoteNN , ChimoteNM . Supplementation of recombinant LH to poor responders in mid‐follicular phase along with recombinant FSH results in better blastocyst formation and implantation rate in antagonist IVF cycles. 31st European Society of Human Reproduction and Embryology (ESHRE); 2015 June 14‐17; Lisbon. 2015:165. ">Dravid 2015</a>; <a href="./references#CD005070-bbs2-0011" title="EvangelioPM , BuendichoIE , YesteAM , GustemMRB , EgeaIB , HernandezNC . Randomized prospective study on the effect of the addition of the effect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response. Revista Iberoamericana de Fertilidad y Reproduccion Humana2011;28(3):3. ">Evangelio 2011</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0016" title="FerrarettiAP , GianaroliL , MotrenkoT , FelicianiE , TabanelliC , MagliMC . LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172] ">Ferraretti 2014</a>; <a href="./references#CD005070-bbs2-0032" title="RuvoloG , BoscoL , PaneA , MoriciG , CittadiniE , RoccheriMC . Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertility and Sterility2007;87(3):542‐6. ">Ruvolo 2007</a>; <a href="./references#CD005070-bbs2-0036" title="YounisJS , IzhakiI , Ben‐AmiM . The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF‐ET: A prospective randomized controlled study. Fertility and Sterility2014;102(3):e23. ">Younis 2014</a>). In five studies, poor responders were defined as women with a previous low response in an IVF/ICSI cycle in terms of follicle growth, which was not further specified (<a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0016" title="FerrarettiAP , GianaroliL , MotrenkoT , FelicianiE , TabanelliC , MagliMC . LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172] ">Ferraretti 2014</a>; <a href="./references#CD005070-bbs2-0032" title="RuvoloG , BoscoL , PaneA , MoriciG , CittadiniE , RoccheriMC . Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertility and Sterility2007;87(3):542‐6. ">Ruvolo 2007</a>; <a href="./references#CD005070-bbs2-0036" title="YounisJS , IzhakiI , Ben‐AmiM . The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF‐ET: A prospective randomized controlled study. Fertility and Sterility2014;102(3):e23. ">Younis 2014</a>). One study defined poor responders as women with at least two cycles with one of the following criteria: three oocytes retrieved, three follicles of 16 mm diameter on hCG day and maximal E2 (estradiol) &lt; 500 pg/ml (<a href="./references#CD005070-bbs2-0008" title="DemirolA , GurganT , GirginB . Supplementation of rec‐LH for poor responder patients. Abstracts of the 21st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2005 June 19‐22; Copenhagen. 2005:i74. ">Demirol 2005</a>). One study defined poor responders on the basis of their low AMH (anti‐mullerian hormone) levels and antral follicle count (<a href="./references#CD005070-bbs2-0010" title="DravidRM , ChimoteBN , ChimoteAN , ChimoteNN , ChimoteNM . Supplementation of recombinant LH to poor responders in mid‐follicular phase along with recombinant FSH results in better blastocyst formation and implantation rate in antagonist IVF cycles. 31st European Society of Human Reproduction and Embryology (ESHRE); 2015 June 14‐17; Lisbon. 2015:165. ">Dravid 2015</a>). One other study defined poor responders when they were 37 years or younger or had a basal follicle‐stimulating hormone (FSH) level of &gt; 10 or had four or less follicles in a previous IVF/ICSI cycle (<a href="./references#CD005070-bbs2-0011" title="EvangelioPM , BuendichoIE , YesteAM , GustemMRB , EgeaIB , HernandezNC . Randomized prospective study on the effect of the addition of the effect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response. Revista Iberoamericana de Fertilidad y Reproduccion Humana2011;28(3):3. ">Evangelio 2011</a>). </p> <p>One study excluded poor responders (defined as having a previous unsuccessful IVF cycle due to two or less oocytes recovered) (<a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>). </p> <p>Twelve studies included women of advanced age (<a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>; <a href="./references#CD005070-bbs2-0004" title="BarrenetxeaG , AgirregoikaJA , JimenezMR , Lopez de LarruzeaA , GanzabalT , CarboneroK . Ovarian response and pregnancy outcome in poor‐responder women: a randomised controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertility and Sterility2008;89(3):546‐53. ">Barrenetxea 2008</a>; <a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0025" title="MatorrasR , PrietoB , ExpositoA , MendozaR , CrisolL , HerranzP , et al. Mid‐follicular LH supplementation in women aged 35‐39 years undergoing ICSI cycles: a randomized controlled study. Reproductive Biomedicine Online2009;19(6):879‐87. ">Matorras 2009</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0028" title="NazzaroA , SalemoA . Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH‐antagonist protocol improves implantation and pregnancy rates. Fertility and Sterility2012;98(3):S280. ">Nazzaro 2012</a>; <a href="./references#CD005070-bbs2-0034" title="Van DerHouwenL , KonigTE , OverbeekA , HendriksML , BeemsterboerSN , KuchenbeckerWK , et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction2011; Vol. 26:i314‐5. ">Van der Houwen 2011</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>; <a href="./references#CD005070-bbs2-0036" title="YounisJS , IzhakiI , Ben‐AmiM . The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF‐ET: A prospective randomized controlled study. Fertility and Sterility2014;102(3):e23. ">Younis 2014</a>). Definitions of advanced age varied amongst the studies. Three studies defined advanced age as 35 years or older (<a href="./references#CD005070-bbs2-0034" title="Van DerHouwenL , KonigTE , OverbeekA , HendriksML , BeemsterboerSN , KuchenbeckerWK , et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction2011; Vol. 26:i314‐5. ">Van der Houwen 2011</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>; <a href="./references#CD005070-bbs2-0036" title="YounisJS , IzhakiI , Ben‐AmiM . The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF‐ET: A prospective randomized controlled study. Fertility and Sterility2014;102(3):e23. ">Younis 2014)</a>; six studies as between 35 and 41 years of age (<a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0025" title="MatorrasR , PrietoB , ExpositoA , MendozaR , CrisolL , HerranzP , et al. Mid‐follicular LH supplementation in women aged 35‐39 years undergoing ICSI cycles: a randomized controlled study. Reproductive Biomedicine Online2009;19(6):879‐87. ">Matorras 2009</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0028" title="NazzaroA , SalemoA . Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH‐antagonist protocol improves implantation and pregnancy rates. Fertility and Sterility2012;98(3):S280. ">Nazzaro 2012</a>); one study as between 38 and 44 years of age (<a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>); one study as between 36 and 39 years of age (<a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>); and one study as 40 years or older (<a href="./references#CD005070-bbs2-0004" title="BarrenetxeaG , AgirregoikaJA , JimenezMR , Lopez de LarruzeaA , GanzabalT , CarboneroK . Ovarian response and pregnancy outcome in poor‐responder women: a randomised controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertility and Sterility2008;89(3):546‐53. ">Barrenetxea 2008</a>). </p> </section> <section id="CD005070-sec-0066"> <h5 class="title">Interventions</h5> <section id="CD005070-sec-0067"> <h6 class="title">rLH combined with rFSH to rFSH alone in GnRH agonist downregulated cycles</h6> <p>Twenty‐five studies totalling 6100 women compared rLH combined with rFSH to rFSH alone in GnRH agonist downregulated IVF or ICSI cycles (<a href="./references#CD005070-bbs2-0001" title="AbdelmassihV , SalgueiroR , AbdelmassihC , CarizzaC . Less miscarriage rate using LH (rLH) in GnRH agonists long protocols. Twenty‐Second Annual Meeting of the European Society of Human Reproduction and Embryology; 2006 June 18‐21. Prague: ESHRE, 2006. ">Abdelmassih 2006</a>; <a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>; <a href="./references#CD005070-bbs2-0003" title="BalaschJ , CreusM , FabreguesF , CivicoS , CarmonaF , PuertoB , et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle‐stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary‐suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics2001;18(5):250‐6. ">Balasch 2001</a>; <a href="./references#CD005070-bbs2-0004" title="BarrenetxeaG , AgirregoikaJA , JimenezMR , Lopez de LarruzeaA , GanzabalT , CarboneroK . Ovarian response and pregnancy outcome in poor‐responder women: a randomised controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertility and Sterility2008;89(3):546‐53. ">Barrenetxea 2008</a>; <a href="./references#CD005070-bbs2-0005" title="BerkkanogluM , IsikogluM , AydinD , OzgurK . Clinical effects of ovulation induction with recombinant follicle‐stimulating hormone supplemented with recombinant luteinizing hormone or low‐dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertilility and Sterility2007;88(3):665‐9. ">Berkkanoglu 2007</a>; <a href="./references#CD005070-bbs2-0007" title="CasertaD , LisiF , MarciR , CiardoF , FaziA , LisiR , et al. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?. Gynecological Endocrinology2011;27:862‐6. ">Caserta 2011</a>; <a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>; <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0016" title="FerrarettiAP , GianaroliL , MotrenkoT , FelicianiE , TabanelliC , MagliMC . LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172] ">Ferraretti 2014</a>; <a href="./references#CD005070-bbs2-0018" title="HumaidanP , BungumM , BungumL , Yding AndersenC . Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down‐regulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedine2004;8(6):635‐43. ">Humaidan 2004</a>; <a href="./references#CD005070-bbs2-0020" title="KovacsP , KovatsT , KaaliSG . Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertility and Sterility2010;93(2):475‐9. ">Kovacs 2010</a>; <a href="./references#CD005070-bbs2-0022" title="LisiF , RinaldiL , FishelS , CasertaD , LisiR , CampbellA . Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertility and Sterility2005;83(2):309‐15. ">Lisi 2005</a>; <a href="./references#CD005070-bbs2-0023" title="LisiF , CasertaD , MontaninoM , BerlinghieriV , BielliW , CarfagnaP , et al. Recombinant luteinizing hormone priming in multiple follicular stimulation for in‐vitro fertilization downregulated patients. Gynecological Endocrinology2012;28(9):674‐7. [DOI: 10.3109/09513590.2011.652716] ">Lisi 2012</a>; <a href="./references#CD005070-bbs2-0024" title="MarrsR , MeldrumD , MuasherS , SchoolcraftW , WerlinL , KellyE . Randomized trial to compare the effect of recombinant FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive Biomedicine Online2003;8(2):175‐82. ">Marrs 2003</a>; <a href="./references#CD005070-bbs2-0025" title="MatorrasR , PrietoB , ExpositoA , MendozaR , CrisolL , HerranzP , et al. Mid‐follicular LH supplementation in women aged 35‐39 years undergoing ICSI cycles: a randomized controlled study. Reproductive Biomedicine Online2009;19(6):879‐87. ">Matorras 2009</a>; <a href="./references#CD005070-bbs2-0026" title="MohseniF , Dehgani FirouzabadiR , YariN , EtebaryS . Results of adding recombinant LH in normoresponder patients for assisted reproductive technology treatment: a prospective randomized control trial. International Journal of Fertility and Sterility2013;7:112. ">Mohseni 2013</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0028" title="NazzaroA , SalemoA . Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH‐antagonist protocol improves implantation and pregnancy rates. Fertility and Sterility2012;98(3):S280. ">Nazzaro 2012</a>; <a href="./references#CD005070-bbs2-0029" title="Nyboe AndersenA , HumaidanP , FriedG , HauskenJ , AntilaL , BangsbøllS , et al. Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre,prospective, randomized, controlled trial. Human Reproduction2008;23(2):427‐34. ">Nyboe Andersen 2008</a>; <a href="./references#CD005070-bbs2-0030" title="PezzutoA , FerrariB , CoppolaF , NardelliGB . LH supplementation in down‐regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecological Endocrinology2010;26(2):118‐24. ">Pezzuto 2010</a>; <a href="./references#CD005070-bbs2-0031" title="RaziMH , MohseniF , Dehghani FirouzabadiR , JanatiS , YariN , EtebaryS . Results from adding recombinant LH for assisted reproductive technology treatment: A randomized control trial. Iranian Journal of Reproductive Medicine2014;12(2):111‐6. ">Razi 2014</a>; <a href="./references#CD005070-bbs2-0032" title="RuvoloG , BoscoL , PaneA , MoriciG , CittadiniE , RoccheriMC . Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertility and Sterility2007;87(3):542‐6. ">Ruvolo 2007</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>). </p> <p>Nineteen of 25 studies started the GnRH agonist downregulation in the mid luteal phase of the preceding cycle (<a href="./references#CD005070-bbs2-0001" title="AbdelmassihV , SalgueiroR , AbdelmassihC , CarizzaC . Less miscarriage rate using LH (rLH) in GnRH agonists long protocols. Twenty‐Second Annual Meeting of the European Society of Human Reproduction and Embryology; 2006 June 18‐21. Prague: ESHRE, 2006. ">Abdelmassih 2006</a>; <a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>; <a href="./references#CD005070-bbs2-0003" title="BalaschJ , CreusM , FabreguesF , CivicoS , CarmonaF , PuertoB , et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle‐stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary‐suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics2001;18(5):250‐6. ">Balasch 2001</a>; <a href="./references#CD005070-bbs2-0007" title="CasertaD , LisiF , MarciR , CiardoF , FaziA , LisiR , et al. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?. Gynecological Endocrinology2011;27:862‐6. ">Caserta 2011</a>; <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0016" title="FerrarettiAP , GianaroliL , MotrenkoT , FelicianiE , TabanelliC , MagliMC . LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172] ">Ferraretti 2014</a>; <a href="./references#CD005070-bbs2-0018" title="HumaidanP , BungumM , BungumL , Yding AndersenC . Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down‐regulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedine2004;8(6):635‐43. ">Humaidan 2004</a>; <a href="./references#CD005070-bbs2-0020" title="KovacsP , KovatsT , KaaliSG . Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertility and Sterility2010;93(2):475‐9. ">Kovacs 2010</a>; <a href="./references#CD005070-bbs2-0022" title="LisiF , RinaldiL , FishelS , CasertaD , LisiR , CampbellA . Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertility and Sterility2005;83(2):309‐15. ">Lisi 2005</a>; <a href="./references#CD005070-bbs2-0023" title="LisiF , CasertaD , MontaninoM , BerlinghieriV , BielliW , CarfagnaP , et al. Recombinant luteinizing hormone priming in multiple follicular stimulation for in‐vitro fertilization downregulated patients. Gynecological Endocrinology2012;28(9):674‐7. [DOI: 10.3109/09513590.2011.652716] ">Lisi 2012</a>; <a href="./references#CD005070-bbs2-0024" title="MarrsR , MeldrumD , MuasherS , SchoolcraftW , WerlinL , KellyE . Randomized trial to compare the effect of recombinant FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive Biomedicine Online2003;8(2):175‐82. ">Marrs 2003</a>; <a href="./references#CD005070-bbs2-0025" title="MatorrasR , PrietoB , ExpositoA , MendozaR , CrisolL , HerranzP , et al. Mid‐follicular LH supplementation in women aged 35‐39 years undergoing ICSI cycles: a randomized controlled study. Reproductive Biomedicine Online2009;19(6):879‐87. ">Matorras 2009</a>; <a href="./references#CD005070-bbs2-0026" title="MohseniF , Dehgani FirouzabadiR , YariN , EtebaryS . Results of adding recombinant LH in normoresponder patients for assisted reproductive technology treatment: a prospective randomized control trial. International Journal of Fertility and Sterility2013;7:112. ">Mohseni 2013</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0029" title="Nyboe AndersenA , HumaidanP , FriedG , HauskenJ , AntilaL , BangsbøllS , et al. Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre,prospective, randomized, controlled trial. Human Reproduction2008;23(2):427‐34. ">Nyboe Andersen 2008</a>; <a href="./references#CD005070-bbs2-0030" title="PezzutoA , FerrariB , CoppolaF , NardelliGB . LH supplementation in down‐regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecological Endocrinology2010;26(2):118‐24. ">Pezzuto 2010</a>; <a href="./references#CD005070-bbs2-0031" title="RaziMH , MohseniF , Dehghani FirouzabadiR , JanatiS , YariN , EtebaryS . Results from adding recombinant LH for assisted reproductive technology treatment: A randomized control trial. Iranian Journal of Reproductive Medicine2014;12(2):111‐6. ">Razi 2014</a>); and six started in the follicular phase (<a href="./references#CD005070-bbs2-0004" title="BarrenetxeaG , AgirregoikaJA , JimenezMR , Lopez de LarruzeaA , GanzabalT , CarboneroK . Ovarian response and pregnancy outcome in poor‐responder women: a randomised controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertility and Sterility2008;89(3):546‐53. ">Barrenetxea 2008</a>; <a href="./references#CD005070-bbs2-0005" title="BerkkanogluM , IsikogluM , AydinD , OzgurK . Clinical effects of ovulation induction with recombinant follicle‐stimulating hormone supplemented with recombinant luteinizing hormone or low‐dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertilility and Sterility2007;88(3):665‐9. ">Berkkanoglu 2007</a>; <a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>; <a href="./references#CD005070-bbs2-0028" title="NazzaroA , SalemoA . Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH‐antagonist protocol improves implantation and pregnancy rates. Fertility and Sterility2012;98(3):S280. ">Nazzaro 2012</a>; <a href="./references#CD005070-bbs2-0032" title="RuvoloG , BoscoL , PaneA , MoriciG , CittadiniE , RoccheriMC . Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertility and Sterility2007;87(3):542‐6. ">Ruvolo 2007</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>). </p> <p>Seven of the 25 studies started with an initial dose of rFSH for ovarian stimulation of 150 IU with a dose of rLH of 37.5 IU, 75 IU, or 150 IU (<a href="./references#CD005070-bbs2-0007" title="CasertaD , LisiF , MarciR , CiardoF , FaziA , LisiR , et al. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?. Gynecological Endocrinology2011;27:862‐6. ">Caserta 2011</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0017" title="GriesingerG , Schultze‐MosgauA , DafopoulosK , SchroederA , SchroerA , vonOtteS , et al. Recombinant luteinizing hormone supplementation to recombinant follicle‐stimulating hormone induced ovarian hyperstimulation in the GnRH‐antagonist multiple‐dose protocol. Human Reproduction2005;20(5):1200‐6. ">Griesinger 2005</a>; <a href="./references#CD005070-bbs2-0020" title="KovacsP , KovatsT , KaaliSG . Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertility and Sterility2010;93(2):475‐9. ">Kovacs 2010</a>; <a href="./references#CD005070-bbs2-0022" title="LisiF , RinaldiL , FishelS , CasertaD , LisiR , CampbellA . Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertility and Sterility2005;83(2):309‐15. ">Lisi 2005</a>; <a href="./references#CD005070-bbs2-0023" title="LisiF , CasertaD , MontaninoM , BerlinghieriV , BielliW , CarfagnaP , et al. Recombinant luteinizing hormone priming in multiple follicular stimulation for in‐vitro fertilization downregulated patients. Gynecological Endocrinology2012;28(9):674‐7. [DOI: 10.3109/09513590.2011.652716] ">Lisi 2012</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>). Twelve studies used an initial dose for ovarian stimulation of ≥ 225 IU rFSH (<a href="./references#CD005070-bbs2-0001" title="AbdelmassihV , SalgueiroR , AbdelmassihC , CarizzaC . Less miscarriage rate using LH (rLH) in GnRH agonists long protocols. Twenty‐Second Annual Meeting of the European Society of Human Reproduction and Embryology; 2006 June 18‐21. Prague: ESHRE, 2006. ">Abdelmassih 2006</a>; <a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>; <a href="./references#CD005070-bbs2-0003" title="BalaschJ , CreusM , FabreguesF , CivicoS , CarmonaF , PuertoB , et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle‐stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary‐suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics2001;18(5):250‐6. ">Balasch 2001</a>; <a href="./references#CD005070-bbs2-0004" title="BarrenetxeaG , AgirregoikaJA , JimenezMR , Lopez de LarruzeaA , GanzabalT , CarboneroK . Ovarian response and pregnancy outcome in poor‐responder women: a randomised controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertility and Sterility2008;89(3):546‐53. ">Barrenetxea 2008</a>; <a href="./references#CD005070-bbs2-0005" title="BerkkanogluM , IsikogluM , AydinD , OzgurK . Clinical effects of ovulation induction with recombinant follicle‐stimulating hormone supplemented with recombinant luteinizing hormone or low‐dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertilility and Sterility2007;88(3):665‐9. ">Berkkanoglu 2007</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0016" title="FerrarettiAP , GianaroliL , MotrenkoT , FelicianiE , TabanelliC , MagliMC . LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172] ">Ferraretti 2014</a>; <a href="./references#CD005070-bbs2-0024" title="MarrsR , MeldrumD , MuasherS , SchoolcraftW , WerlinL , KellyE . Randomized trial to compare the effect of recombinant FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive Biomedicine Online2003;8(2):175‐82. ">Marrs 2003</a>; <a href="./references#CD005070-bbs2-0025" title="MatorrasR , PrietoB , ExpositoA , MendozaR , CrisolL , HerranzP , et al. Mid‐follicular LH supplementation in women aged 35‐39 years undergoing ICSI cycles: a randomized controlled study. Reproductive Biomedicine Online2009;19(6):879‐87. ">Matorras 2009</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0028" title="NazzaroA , SalemoA . Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH‐antagonist protocol improves implantation and pregnancy rates. Fertility and Sterility2012;98(3):S280. ">Nazzaro 2012</a>; <a href="./references#CD005070-bbs2-0030" title="PezzutoA , FerrariB , CoppolaF , NardelliGB . LH supplementation in down‐regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecological Endocrinology2010;26(2):118‐24. ">Pezzuto 2010</a>); and a rLH dose of 75 IU (<a href="./references#CD005070-bbs2-0001" title="AbdelmassihV , SalgueiroR , AbdelmassihC , CarizzaC . Less miscarriage rate using LH (rLH) in GnRH agonists long protocols. Twenty‐Second Annual Meeting of the European Society of Human Reproduction and Embryology; 2006 June 18‐21. Prague: ESHRE, 2006. ">Abdelmassih 2006</a>; <a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>; <a href="./references#CD005070-bbs2-0003" title="BalaschJ , CreusM , FabreguesF , CivicoS , CarmonaF , PuertoB , et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle‐stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary‐suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics2001;18(5):250‐6. ">Balasch 2001</a>; <a href="./references#CD005070-bbs2-0005" title="BerkkanogluM , IsikogluM , AydinD , OzgurK . Clinical effects of ovulation induction with recombinant follicle‐stimulating hormone supplemented with recombinant luteinizing hormone or low‐dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertilility and Sterility2007;88(3):665‐9. ">Berkkanoglu 2007</a>; <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0020" title="KovacsP , KovatsT , KaaliSG . Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertility and Sterility2010;93(2):475‐9. ">Kovacs 2010</a>; <a href="./references#CD005070-bbs2-0022" title="LisiF , RinaldiL , FishelS , CasertaD , LisiR , CampbellA . Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertility and Sterility2005;83(2):309‐15. ">Lisi 2005</a>; <a href="./references#CD005070-bbs2-0023" title="LisiF , CasertaD , MontaninoM , BerlinghieriV , BielliW , CarfagnaP , et al. Recombinant luteinizing hormone priming in multiple follicular stimulation for in‐vitro fertilization downregulated patients. Gynecological Endocrinology2012;28(9):674‐7. [DOI: 10.3109/09513590.2011.652716] ">Lisi 2012</a>; <a href="./references#CD005070-bbs2-0030" title="PezzutoA , FerrariB , CoppolaF , NardelliGB . LH supplementation in down‐regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecological Endocrinology2010;26(2):118‐24. ">Pezzuto 2010</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>); or 150 IU (<a href="./references#CD005070-bbs2-0004" title="BarrenetxeaG , AgirregoikaJA , JimenezMR , Lopez de LarruzeaA , GanzabalT , CarboneroK . Ovarian response and pregnancy outcome in poor‐responder women: a randomised controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertility and Sterility2008;89(3):546‐53. ">Barrenetxea 2008</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0018" title="HumaidanP , BungumM , BungumL , Yding AndersenC . Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down‐regulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedine2004;8(6):635‐43. ">Humaidan 2004</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0028" title="NazzaroA , SalemoA . Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH‐antagonist protocol improves implantation and pregnancy rates. Fertility and Sterility2012;98(3):S280. ">Nazzaro 2012</a>). Four studies adjusted the initial rFSH dose (150 IU to 225 IU to 300 IU) and the dose of rLH (75 IU to 150 IU) according to the age of the patient (<a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0018" title="HumaidanP , BungumM , BungumL , Yding AndersenC . Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down‐regulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedine2004;8(6):635‐43. ">Humaidan 2004</a>; <a href="./references#CD005070-bbs2-0029" title="Nyboe AndersenA , HumaidanP , FriedG , HauskenJ , AntilaL , BangsbøllS , et al. Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre,prospective, randomized, controlled trial. Human Reproduction2008;23(2):427‐34. ">Nyboe Andersen 2008</a>). Three studies used a stepdown rFSH stimulation protocol: <a href="./references#CD005070-bbs2-0003" title="BalaschJ , CreusM , FabreguesF , CivicoS , CarmonaF , PuertoB , et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle‐stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary‐suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics2001;18(5):250‐6. ">Balasch 2001</a> used 75 IU rLH or 150 IU rLH; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a> used 150 IU rLH; and <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a> used 37.5 IU rLH or 75 IU rLH. In one study the FSH dose was unknown (<a href="./references#CD005070-bbs2-0026" title="MohseniF , Dehgani FirouzabadiR , YariN , EtebaryS . Results of adding recombinant LH in normoresponder patients for assisted reproductive technology treatment: a prospective randomized control trial. International Journal of Fertility and Sterility2013;7:112. ">Mohseni 2013</a>). In four studies, the rLH was started on stimulation day six, two on stimulation day seven and two on stimulation day eight. In two studies the start of rLH depended on follicular response (<a href="./references#CD005070-bbs2-0026" title="MohseniF , Dehgani FirouzabadiR , YariN , EtebaryS . Results of adding recombinant LH in normoresponder patients for assisted reproductive technology treatment: a prospective randomized control trial. International Journal of Fertility and Sterility2013;7:112. ">Mohseni 2013</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>). All studies, except <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>, continued rLH until hCG. </p> </section> <section id="CD005070-sec-0068"> <h6 class="title">rLH combined with rFSH to rFSH alone in GnRH antagonist downregulated cycles</h6> <p>Eleven studies totaling 2025 women compared rLH combined with rFSH to rFSH alone in GnRH antagonist downregulated IVF or ICSI cycles (<a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0008" title="DemirolA , GurganT , GirginB . Supplementation of rec‐LH for poor responder patients. Abstracts of the 21st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2005 June 19‐22; Copenhagen. 2005:i74. ">Demirol 2005</a>; <a href="./references#CD005070-bbs2-0010" title="DravidRM , ChimoteBN , ChimoteAN , ChimoteNN , ChimoteNM . Supplementation of recombinant LH to poor responders in mid‐follicular phase along with recombinant FSH results in better blastocyst formation and implantation rate in antagonist IVF cycles. 31st European Society of Human Reproduction and Embryology (ESHRE); 2015 June 14‐17; Lisbon. 2015:165. ">Dravid 2015</a>; <a href="./references#CD005070-bbs2-0011" title="EvangelioPM , BuendichoIE , YesteAM , GustemMRB , EgeaIB , HernandezNC . Randomized prospective study on the effect of the addition of the effect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response. Revista Iberoamericana de Fertilidad y Reproduccion Humana2011;28(3):3. ">Evangelio 2011</a>; <a href="./references#CD005070-bbs2-0014" title="Fernández RamírezMJ , MonzóA , García‐GimenoT , RubioJM , MontañanaV , DuqueC . Role of LH administration during the follicular phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF [Papel de la administracion de LH en el curso de la fase folicular en mujeres con riesgo de pobre respuesta en ciclos de estimulacion con FSH y cetrorelix para FIV]. Revista Iberoamericana de Fertilidad y Reproduccion Humana2006;23(5):281‐90. ">Fernandez‐Ramirez 2006</a>; <a href="./references#CD005070-bbs2-0017" title="GriesingerG , Schultze‐MosgauA , DafopoulosK , SchroederA , SchroerA , vonOtteS , et al. Recombinant luteinizing hormone supplementation to recombinant follicle‐stimulating hormone induced ovarian hyperstimulation in the GnRH‐antagonist multiple‐dose protocol. Human Reproduction2005;20(5):1200‐6. ">Griesinger 2005</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0021" title="Levi‐SettiPE , CavagnaM , BullettiC . Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of rFSH alone and in combination with rLH. European Journal of Obstetrics and Gynecology and Reproductive Biology2006;126:212‐16. ">Levi‐Setti 2006</a>; <a href="./references#CD005070-bbs2-0034" title="Van DerHouwenL , KonigTE , OverbeekA , HendriksML , BeemsterboerSN , KuchenbeckerWK , et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction2011; Vol. 26:i314‐5. ">Van der Houwen 2011</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>; <a href="./references#CD005070-bbs2-0036" title="YounisJS , IzhakiI , Ben‐AmiM . The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF‐ET: A prospective randomized controlled study. Fertility and Sterility2014;102(3):e23. ">Younis 2014</a>). </p> <p>Ten studies started rLH combined with rFSH together with a GnRH antagonist and continued until day of hCG (<a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0008" title="DemirolA , GurganT , GirginB . Supplementation of rec‐LH for poor responder patients. Abstracts of the 21st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2005 June 19‐22; Copenhagen. 2005:i74. ">Demirol 2005</a>; <a href="./references#CD005070-bbs2-0011" title="EvangelioPM , BuendichoIE , YesteAM , GustemMRB , EgeaIB , HernandezNC . Randomized prospective study on the effect of the addition of the effect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response. Revista Iberoamericana de Fertilidad y Reproduccion Humana2011;28(3):3. ">Evangelio 2011</a>; <a href="./references#CD005070-bbs2-0014" title="Fernández RamírezMJ , MonzóA , García‐GimenoT , RubioJM , MontañanaV , DuqueC . Role of LH administration during the follicular phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF [Papel de la administracion de LH en el curso de la fase folicular en mujeres con riesgo de pobre respuesta en ciclos de estimulacion con FSH y cetrorelix para FIV]. Revista Iberoamericana de Fertilidad y Reproduccion Humana2006;23(5):281‐90. ">Fernandez‐Ramirez 2006</a>; <a href="./references#CD005070-bbs2-0017" title="GriesingerG , Schultze‐MosgauA , DafopoulosK , SchroederA , SchroerA , vonOtteS , et al. Recombinant luteinizing hormone supplementation to recombinant follicle‐stimulating hormone induced ovarian hyperstimulation in the GnRH‐antagonist multiple‐dose protocol. Human Reproduction2005;20(5):1200‐6. ">Griesinger 2005</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0021" title="Levi‐SettiPE , CavagnaM , BullettiC . Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of rFSH alone and in combination with rLH. European Journal of Obstetrics and Gynecology and Reproductive Biology2006;126:212‐16. ">Levi‐Setti 2006</a>; <a href="./references#CD005070-bbs2-0034" title="Van DerHouwenL , KonigTE , OverbeekA , HendriksML , BeemsterboerSN , KuchenbeckerWK , et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction2011; Vol. 26:i314‐5. ">Van der Houwen 2011</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>; <a href="./references#CD005070-bbs2-0036" title="YounisJS , IzhakiI , Ben‐AmiM . The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF‐ET: A prospective randomized controlled study. Fertility and Sterility2014;102(3):e23. ">Younis 2014</a>). One study started the GnRH antagonist on stimulation day six (<a href="./references#CD005070-bbs2-0010" title="DravidRM , ChimoteBN , ChimoteAN , ChimoteNN , ChimoteNM . Supplementation of recombinant LH to poor responders in mid‐follicular phase along with recombinant FSH results in better blastocyst formation and implantation rate in antagonist IVF cycles. 31st European Society of Human Reproduction and Embryology (ESHRE); 2015 June 14‐17; Lisbon. 2015:165. ">Dravid 2015</a>). Four studies used an initial dose for ovarian stimulation of ≥ 225 IU rFSH (<a href="./references#CD005070-bbs2-0014" title="Fernández RamírezMJ , MonzóA , García‐GimenoT , RubioJM , MontañanaV , DuqueC . Role of LH administration during the follicular phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF [Papel de la administracion de LH en el curso de la fase folicular en mujeres con riesgo de pobre respuesta en ciclos de estimulacion con FSH y cetrorelix para FIV]. Revista Iberoamericana de Fertilidad y Reproduccion Humana2006;23(5):281‐90. ">Fernandez‐Ramirez 2006</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0034" title="Van DerHouwenL , KonigTE , OverbeekA , HendriksML , BeemsterboerSN , KuchenbeckerWK , et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction2011; Vol. 26:i314‐5. ">Van der Houwen 2011</a>; <a href="./references#CD005070-bbs2-0036" title="YounisJS , IzhakiI , Ben‐AmiM . The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF‐ET: A prospective randomized controlled study. Fertility and Sterility2014;102(3):e23. ">Younis 2014</a>). Two studies used 225 IU rFSH in the rFSH alone group and 150 IU in the rLH combined with rFSH group (<a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0021" title="Levi‐SettiPE , CavagnaM , BullettiC . Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of rFSH alone and in combination with rLH. European Journal of Obstetrics and Gynecology and Reproductive Biology2006;126:212‐16. ">Levi‐Setti 2006</a>). One study used 150 IU rFSH in both groups (<a href="./references#CD005070-bbs2-0010" title="DravidRM , ChimoteBN , ChimoteAN , ChimoteNN , ChimoteNM . Supplementation of recombinant LH to poor responders in mid‐follicular phase along with recombinant FSH results in better blastocyst formation and implantation rate in antagonist IVF cycles. 31st European Society of Human Reproduction and Embryology (ESHRE); 2015 June 14‐17; Lisbon. 2015:165. ">Dravid 2015</a>). One study used a step‐down rFSH stimulation protocol (<a href="./references#CD005070-bbs2-0008" title="DemirolA , GurganT , GirginB . Supplementation of rec‐LH for poor responder patients. Abstracts of the 21st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2005 June 19‐22; Copenhagen. 2005:i74. ">Demirol 2005</a>). Two studies adjusted the initial rFSH dose to the antral follicle count (<a href="./references#CD005070-bbs2-0011" title="EvangelioPM , BuendichoIE , YesteAM , GustemMRB , EgeaIB , HernandezNC . Randomized prospective study on the effect of the addition of the effect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response. Revista Iberoamericana de Fertilidad y Reproduccion Humana2011;28(3):3. ">Evangelio 2011</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>). In four studies, 75 IU rLH was used (<a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0010" title="DravidRM , ChimoteBN , ChimoteAN , ChimoteNN , ChimoteNM . Supplementation of recombinant LH to poor responders in mid‐follicular phase along with recombinant FSH results in better blastocyst formation and implantation rate in antagonist IVF cycles. 31st European Society of Human Reproduction and Embryology (ESHRE); 2015 June 14‐17; Lisbon. 2015:165. ">Dravid 2015</a>; <a href="./references#CD005070-bbs2-0014" title="Fernández RamírezMJ , MonzóA , García‐GimenoT , RubioJM , MontañanaV , DuqueC . Role of LH administration during the follicular phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF [Papel de la administracion de LH en el curso de la fase folicular en mujeres con riesgo de pobre respuesta en ciclos de estimulacion con FSH y cetrorelix para FIV]. Revista Iberoamericana de Fertilidad y Reproduccion Humana2006;23(5):281‐90. ">Fernandez‐Ramirez 2006</a>; <a href="./references#CD005070-bbs2-0021" title="Levi‐SettiPE , CavagnaM , BullettiC . Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of rFSH alone and in combination with rLH. European Journal of Obstetrics and Gynecology and Reproductive Biology2006;126:212‐16. ">Levi‐Setti 2006</a>), and in five studies, 150 IU rLH was used (<a href="./references#CD005070-bbs2-0008" title="DemirolA , GurganT , GirginB . Supplementation of rec‐LH for poor responder patients. Abstracts of the 21st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2005 June 19‐22; Copenhagen. 2005:i74. ">Demirol 2005</a>; <a href="./references#CD005070-bbs2-0017" title="GriesingerG , Schultze‐MosgauA , DafopoulosK , SchroederA , SchroerA , vonOtteS , et al. Recombinant luteinizing hormone supplementation to recombinant follicle‐stimulating hormone induced ovarian hyperstimulation in the GnRH‐antagonist multiple‐dose protocol. Human Reproduction2005;20(5):1200‐6. ">Griesinger 2005</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0034" title="Van DerHouwenL , KonigTE , OverbeekA , HendriksML , BeemsterboerSN , KuchenbeckerWK , et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction2011; Vol. 26:i314‐5. ">Van der Houwen 2011</a>; <a href="./references#CD005070-bbs2-0036" title="YounisJS , IzhakiI , Ben‐AmiM . The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF‐ET: A prospective randomized controlled study. Fertility and Sterility2014;102(3):e23. ">Younis 2014</a>). One study adjusted the rLH dose to the individual patient characteristics in a 1:2 or 1:3 rate to rFSH (<a href="./references#CD005070-bbs2-0011" title="EvangelioPM , BuendichoIE , YesteAM , GustemMRB , EgeaIB , HernandezNC . Randomized prospective study on the effect of the addition of the effect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response. Revista Iberoamericana de Fertilidad y Reproduccion Humana2011;28(3):3. ">Evangelio 2011</a>). Another study supplemented 75 IU rLH or 150 IU rLH (<a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>). </p> </section> </section> <section id="CD005070-sec-0069"> <h5 class="title">Outcomes</h5> <p>Regarding the primary outcomes on effectiveness and safety, four of the included studies reported the live birth rate (<a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0016" title="FerrarettiAP , GianaroliL , MotrenkoT , FelicianiE , TabanelliC , MagliMC . LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172] ">Ferraretti 2014</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>), and six studies reported ovarian hyperstimulation syndrome (<a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0007" title="CasertaD , LisiF , MarciR , CiardoF , FaziA , LisiR , et al. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?. Gynecological Endocrinology2011;27:862‐6. ">Caserta 2011</a>; <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0021" title="Levi‐SettiPE , CavagnaM , BullettiC . Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of rFSH alone and in combination with rLH. European Journal of Obstetrics and Gynecology and Reproductive Biology2006;126:212‐16. ">Levi‐Setti 2006</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>). </p> <p>A total of 19 studies reported ongoing pregnancy (<a href="./references#CD005070-bbs2-0003" title="BalaschJ , CreusM , FabreguesF , CivicoS , CarmonaF , PuertoB , et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle‐stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary‐suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics2001;18(5):250‐6. ">Balasch 2001</a>, <a href="./references#CD005070-bbs2-0004" title="BarrenetxeaG , AgirregoikaJA , JimenezMR , Lopez de LarruzeaA , GanzabalT , CarboneroK . Ovarian response and pregnancy outcome in poor‐responder women: a randomised controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertility and Sterility2008;89(3):546‐53. ">Barrenetxea 2008</a>; <a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0008" title="DemirolA , GurganT , GirginB . Supplementation of rec‐LH for poor responder patients. Abstracts of the 21st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2005 June 19‐22; Copenhagen. 2005:i74. ">Demirol 2005</a>; <a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>; <a href="./references#CD005070-bbs2-0014" title="Fernández RamírezMJ , MonzóA , García‐GimenoT , RubioJM , MontañanaV , DuqueC . Role of LH administration during the follicular phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF [Papel de la administracion de LH en el curso de la fase folicular en mujeres con riesgo de pobre respuesta en ciclos de estimulacion con FSH y cetrorelix para FIV]. Revista Iberoamericana de Fertilidad y Reproduccion Humana2006;23(5):281‐90. ">Fernandez‐Ramirez 2006</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>;<a href="./references#CD005070-bbs2-0017" title="GriesingerG , Schultze‐MosgauA , DafopoulosK , SchroederA , SchroerA , vonOtteS , et al. Recombinant luteinizing hormone supplementation to recombinant follicle‐stimulating hormone induced ovarian hyperstimulation in the GnRH‐antagonist multiple‐dose protocol. Human Reproduction2005;20(5):1200‐6. ">Griesinger 2005</a>; <a href="./references#CD005070-bbs2-0034" title="Van DerHouwenL , KonigTE , OverbeekA , HendriksML , BeemsterboerSN , KuchenbeckerWK , et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction2011; Vol. 26:i314‐5. ">Van der Houwen 2011</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0020" title="KovacsP , KovatsT , KaaliSG . Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertility and Sterility2010;93(2):475‐9. ">Kovacs 2010</a>; <a href="./references#CD005070-bbs2-0021" title="Levi‐SettiPE , CavagnaM , BullettiC . Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of rFSH alone and in combination with rLH. European Journal of Obstetrics and Gynecology and Reproductive Biology2006;126:212‐16. ">Levi‐Setti 2006</a>; <a href="./references#CD005070-bbs2-0022" title="LisiF , RinaldiL , FishelS , CasertaD , LisiR , CampbellA . Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertility and Sterility2005;83(2):309‐15. ">Lisi 2005</a>; <a href="./references#CD005070-bbs2-0025" title="MatorrasR , PrietoB , ExpositoA , MendozaR , CrisolL , HerranzP , et al. Mid‐follicular LH supplementation in women aged 35‐39 years undergoing ICSI cycles: a randomized controlled study. Reproductive Biomedicine Online2009;19(6):879‐87. ">Matorras 2009</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0029" title="Nyboe AndersenA , HumaidanP , FriedG , HauskenJ , AntilaL , BangsbøllS , et al. Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre,prospective, randomized, controlled trial. Human Reproduction2008;23(2):427‐34. ">Nyboe Andersen 2008</a>; <a href="./references#CD005070-bbs2-0032" title="RuvoloG , BoscoL , PaneA , MoriciG , CittadiniE , RoccheriMC . Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertility and Sterility2007;87(3):542‐6. ">Ruvolo 2007</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>); 23 studies reported on clinical pregnancy (<a href="./references#CD005070-bbs2-0001" title="AbdelmassihV , SalgueiroR , AbdelmassihC , CarizzaC . Less miscarriage rate using LH (rLH) in GnRH agonists long protocols. Twenty‐Second Annual Meeting of the European Society of Human Reproduction and Embryology; 2006 June 18‐21. Prague: ESHRE, 2006. ">Abdelmassih 2006</a>; <a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>; <a href="./references#CD005070-bbs2-0003" title="BalaschJ , CreusM , FabreguesF , CivicoS , CarmonaF , PuertoB , et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle‐stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary‐suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics2001;18(5):250‐6. ">Balasch 2001</a>, <a href="./references#CD005070-bbs2-0007" title="CasertaD , LisiF , MarciR , CiardoF , FaziA , LisiR , et al. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?. Gynecological Endocrinology2011;27:862‐6. ">Caserta 2011</a>; <a href="./references#CD005070-bbs2-0010" title="DravidRM , ChimoteBN , ChimoteAN , ChimoteNN , ChimoteNM . Supplementation of recombinant LH to poor responders in mid‐follicular phase along with recombinant FSH results in better blastocyst formation and implantation rate in antagonist IVF cycles. 31st European Society of Human Reproduction and Embryology (ESHRE); 2015 June 14‐17; Lisbon. 2015:165. ">Dravid 2015</a>; <a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0014" title="Fernández RamírezMJ , MonzóA , García‐GimenoT , RubioJM , MontañanaV , DuqueC . Role of LH administration during the follicular phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF [Papel de la administracion de LH en el curso de la fase folicular en mujeres con riesgo de pobre respuesta en ciclos de estimulacion con FSH y cetrorelix para FIV]. Revista Iberoamericana de Fertilidad y Reproduccion Humana2006;23(5):281‐90. ">Fernandez‐Ramirez 2006</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>;;<a href="./references#CD005070-bbs2-0018" title="HumaidanP , BungumM , BungumL , Yding AndersenC . Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down‐regulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedine2004;8(6):635‐43. ">Humaidan 2004</a>; <a href="./references#CD005070-bbs2-0034" title="Van DerHouwenL , KonigTE , OverbeekA , HendriksML , BeemsterboerSN , KuchenbeckerWK , et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction2011; Vol. 26:i314‐5. ">Van der Houwen 2011</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0020" title="KovacsP , KovatsT , KaaliSG . Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertility and Sterility2010;93(2):475‐9. ">Kovacs 2010</a>; ; <a href="./references#CD005070-bbs2-0022" title="LisiF , RinaldiL , FishelS , CasertaD , LisiR , CampbellA . Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertility and Sterility2005;83(2):309‐15. ">Lisi 2005</a>; <a href="./references#CD005070-bbs2-0023" title="LisiF , CasertaD , MontaninoM , BerlinghieriV , BielliW , CarfagnaP , et al. Recombinant luteinizing hormone priming in multiple follicular stimulation for in‐vitro fertilization downregulated patients. Gynecological Endocrinology2012;28(9):674‐7. [DOI: 10.3109/09513590.2011.652716] ">Lisi 2012</a>; <a href="./references#CD005070-bbs2-0024" title="MarrsR , MeldrumD , MuasherS , SchoolcraftW , WerlinL , KellyE . Randomized trial to compare the effect of recombinant FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive Biomedicine Online2003;8(2):175‐82. ">Marrs 2003</a>; <a href="./references#CD005070-bbs2-0025" title="MatorrasR , PrietoB , ExpositoA , MendozaR , CrisolL , HerranzP , et al. Mid‐follicular LH supplementation in women aged 35‐39 years undergoing ICSI cycles: a randomized controlled study. Reproductive Biomedicine Online2009;19(6):879‐87. ">Matorras 2009</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0029" title="Nyboe AndersenA , HumaidanP , FriedG , HauskenJ , AntilaL , BangsbøllS , et al. Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre,prospective, randomized, controlled trial. Human Reproduction2008;23(2):427‐34. ">Nyboe Andersen 2008</a>; <a href="./references#CD005070-bbs2-0030" title="PezzutoA , FerrariB , CoppolaF , NardelliGB . LH supplementation in down‐regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecological Endocrinology2010;26(2):118‐24. ">Pezzuto 2010</a>; <a href="./references#CD005070-bbs2-0031" title="RaziMH , MohseniF , Dehghani FirouzabadiR , JanatiS , YariN , EtebaryS . Results from adding recombinant LH for assisted reproductive technology treatment: A randomized control trial. Iranian Journal of Reproductive Medicine2014;12(2):111‐6. ">Razi 2014</a>;<a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>); 13 studies reported on miscarriages (<a href="./references#CD005070-bbs2-0003" title="BalaschJ , CreusM , FabreguesF , CivicoS , CarmonaF , PuertoB , et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle‐stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary‐suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics2001;18(5):250‐6. ">Balasch 2001</a>,.<a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>;<a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0016" title="FerrarettiAP , GianaroliL , MotrenkoT , FelicianiE , TabanelliC , MagliMC . LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172] ">Ferraretti 2014</a>; <a href="./references#CD005070-bbs2-0017" title="GriesingerG , Schultze‐MosgauA , DafopoulosK , SchroederA , SchroerA , vonOtteS , et al. Recombinant luteinizing hormone supplementation to recombinant follicle‐stimulating hormone induced ovarian hyperstimulation in the GnRH‐antagonist multiple‐dose protocol. Human Reproduction2005;20(5):1200‐6. ">Griesinger 2005</a>; <a href="./references#CD005070-bbs2-0018" title="HumaidanP , BungumM , BungumL , Yding AndersenC . Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down‐regulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedine2004;8(6):635‐43. ">Humaidan 2004</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0031" title="RaziMH , MohseniF , Dehghani FirouzabadiR , JanatiS , YariN , EtebaryS . Results from adding recombinant LH for assisted reproductive technology treatment: A randomized control trial. Iranian Journal of Reproductive Medicine2014;12(2):111‐6. ">Razi 2014</a>;<a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>); 11 studies reported on the cancellation rate due to low response (<a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>; <a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0009" title="DePlacidoG , AlviggiC , PerinoA , StrinaI , LisiF , FasolinoA , et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step‐up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction2005;20(2):390‐6. ">De Placido 2005</a>; <a href="./references#CD005070-bbs2-0011" title="EvangelioPM , BuendichoIE , YesteAM , GustemMRB , EgeaIB , HernandezNC . Randomized prospective study on the effect of the addition of the effect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response. Revista Iberoamericana de Fertilidad y Reproduccion Humana2011;28(3):3. ">Evangelio 2011</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>; <a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0016" title="FerrarettiAP , GianaroliL , MotrenkoT , FelicianiE , TabanelliC , MagliMC . LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172] ">Ferraretti 2014</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0027" title="MustersAM , vanWelyM , MastenbroekS , KaaijkEM , ReppingS , van derVeenF , et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction2012;27(1):244‐50. ">Musters 2012</a>; <a href="./references#CD005070-bbs2-0033" title="TarlatzisB , TavmergenE , SzamatowiczM , BarashA , AmitA , LevitasE , et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double‐blind, randomized, prospective study. Human Reproduction2006;21(1):90‐4. ">Tarlatzis 2006</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>); and eight studies reported on the cancellation rate due to imminent ovarian hyperstimulation syndrome (<a href="./references#CD005070-bbs2-0002" title="AllegraA , PaneA , MarinoA , ScaglioneP , RuvoloG , VolpesA . Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3‐6; Stockholm. 2011:i298‐9. ">Allegra 2011</a>; <a href="./references#CD005070-bbs2-0006" title="BoschE , LabartaE , CrespoJ , SimonC , RemohiJ , PellicerA . Impact of luteinizing hormone administration on gonadotropin‐releasing hormone antagonist cycles: An age‐adjusted analysis. Fertility and Sterility2011;95(3):1031‐6. ">Bosch 2011</a>; <a href="./references#CD005070-bbs2-0007" title="CasertaD , LisiF , MarciR , CiardoF , FaziA , LisiR , et al. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?. Gynecological Endocrinology2011;27:862‐6. ">Caserta 2011</a>; <a href="./references#CD005070-bbs2-0015" title="FerrarettiAP , GianaroliL , MagliMC , D'AngeloA , FarfalliV , MontanaroN . Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility2004;82(6):1521‐6. ">Ferraretti 2004</a>; <a href="./references#CD005070-bbs2-0017" title="GriesingerG , Schultze‐MosgauA , DafopoulosK , SchroederA , SchroerA , vonOtteS , et al. Recombinant luteinizing hormone supplementation to recombinant follicle‐stimulating hormone induced ovarian hyperstimulation in the GnRH‐antagonist multiple‐dose protocol. Human Reproduction2005;20(5):1200‐6. ">Griesinger 2005</a>; <a href="./references#CD005070-bbs2-0019" title="KönigTE , van derHouwenLE , OverbeekA , HendriksML , Beutler‐BeemsterboerSN , KuchenbeckerWK , et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction2013;28(10):2804‐12. ">Konig 2013</a>; <a href="./references#CD005070-bbs2-0024" title="MarrsR , MeldrumD , MuasherS , SchoolcraftW , WerlinL , KellyE . Randomized trial to compare the effect of recombinant FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive Biomedicine Online2003;8(2):175‐82. ">Marrs 2003</a>; <a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>). </p> </section> </section> <section id="CD005070-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We excluded 21 studies; 14 studies used interventions that were not relevant to the review, five used designs that were not relevant to the review, and two included participants who did not meet inclusion criteria. </p> <p>Further information on the excluded studies is available in the <a href="https://caaife9dgbgfl2hq5x9bg37hsi.sec.amc.nl/enhanced/doi/10.1002/14651858.CD006919.pub4#CD006919-sec2-0026" target="_blank">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD005070-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD005070-fig-0002">Figure 2</a> and <a href="#CD005070-fig-0003">Figure 3</a> for details. </p> <div class="figure" id="CD005070-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005070-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005070-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005070-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005070-sec-0072"> <h4 class="title">Allocation</h4> <section id="CD005070-sec-0073"> <h5 class="title">Sequence generation</h5> <p>We rated 19 studies at low risk of selection bias for sequence generation, since they used computer randomization or random number tables for sequence generation. For 17 studies the method used in sequence generation was not fully described and we rated them at unclear risk of selection bias in relation to sequence generation. </p> </section> <section id="CD005070-sec-0074"> <h5 class="title">Allocation concealment</h5> <p>Fourteen studies used adequate methods in concealing the allocation, and we judged them at low risk of bias. In the remaining 22 studies, the process involved in concealing the allocation was not adequately described, and we rated them at unclear risk of bias. </p> </section> </section> <section id="CD005070-sec-0075"> <h4 class="title">Blinding</h4> <section id="CD005070-sec-0076"> <h5 class="title">Perfomance bias</h5> <p>Clinicians and participants were not blinded to the interventions in some of the included studies, while others did not report sufficient information on whether or not clinicians and participants were blinded. Non‐blinding of clinicians and participants may not be likely to affect the outcomes of interest, as they are objectively assessed. We, therefore, judged all included studies to be at low risk of bias. </p> </section> <section id="CD005070-sec-0077"> <h5 class="title">Detection bias</h5> <p>Outcome assessors were not blinded in some of the included studies while others did not report sufficient information on whether or not outcome assessors were blinded. Non‐blinding of outcome assessment may not be likely to affect some outcomes of interest as they are objectively assessed. We, therefore, judged all included studies to be at low risk of bias. </p> </section> </section> <section id="CD005070-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>We rated 11 studies at low risk of incomplete outcome data either because there were no withdrawals or losses to follow‐up, or the proportions of withdrawals and reasons for withdrawals were similar across treatment groups and data were analyzed on the basis of intention‐to‐treat. </p> <p>Eighteen studies did not report enough information to make conclusive judgements in respect to attrition bias, and thus we rated them at unclear risk of bias. </p> <p>In the remaining seven studies, the proportions of withdrawals and reasons for withdrawals or losses to follow‐up differed significantly between the treatment groups, and not all women randomized at baseline were included in data analysis; we judged these studies at high risk of bias. </p> </section> <section id="CD005070-sec-0079"> <h4 class="title">Selective reporting</h4> <p>We judged 20 studies to be at low risk of reporting bias since the methods were prespecified. We rated this domain as unclear in 11 studies because we found no sufficient information in the methods section. We rated reporting bias as high in the remaining five studies because there was evidence of selective reporting of outcomes, as data were not available on all the outcomes prespecified in the methods section. </p> </section> <section id="CD005070-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>With respect to other sources of bias, we assessed studies for significant differences in baseline demographic characteristics of participants. We rated 22 studies at low risk of bias, since there were no conflict of interests and there were no other potential sources of bias, such as differences in baseline demographic characteristics. We rated the risk of bias as unclear in 14 studies, because there was insufficient information on differences in baseline characteristics of participants. </p> </section> </section> <section id="CD005070-sec-0081"> <h3 class="title" id="CD005070-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD005070-tbl-0001"><b>Summary of findings for the main comparison</b> Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) versus rFSH alone</a> </p> <section id="CD005070-sec-0082"> <h4 class="title">Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) versus rFSH alone in agonist or antagonist cycles </h4> <section id="CD005070-sec-0083"> <h5 class="title">Primary outcomes</h5> <section id="CD005070-sec-0084"> <h6 class="title">1. Live birth rate</h6> <p>Applying a fixed‐effect model to pool the data, there was no evidence of a difference in live birth rate between ovarian stimulation with rLH combined with rFSH and ovarian stimulation with rFSH alone (odds ratio (OR) 1.32, 95% confidence interval (CI) 0.85 to 2.06; n = 499; studies = 4; I<sup>2</sup> = 63%, very low‐quality of evidence) (<a href="./full#CD005070-tbl-0001">summary of findings Table for the main comparison</a>). The evidence suggests that if the live birth rate following treatment with rFSH alone is 17%, the range of live birth rate varies between 15% and 30% using rLH combined with rFSH (<a href="./references#CD005070-fig-0007" title="">Analysis 1.1</a>, <a href="#CD005070-fig-0004">Figure 4</a>). Applying a random‐effects model to pool the data resulted in an OR of 1.43 (95% CI 0.85 to 2.06). </p> <div class="figure" id="CD005070-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 rLH plus rFSH versus rFSH alone for OS in IVF or ICSI treatment cycles, outcome: 1.1 Live birth rate." data-id="CD005070-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 rLH plus rFSH versus rFSH alone for OS in IVF or ICSI treatment cycles, outcome: 1.1 Live birth rate. </p> </div> </div> </div> <section id="CD005070-sec-0085"> <p><b>Subgroup analysis 1.1: Downregulating agent used</b></p> <p>There was no good evidence that the effects of the intervention differed by type of analogue (test for subgroup differences: Chi² = 1.73, df = 1 (P = 0.19), I² = 42.3%), but there were too few studies to reach any conclusions. <a href="./references#CD005070-fig-0007" title="">Analysis 1.1</a> </p> </section> <section id="CD005070-sec-0086"> <p><b>Subgroup analysis 1.2: Ovarian response</b></p> <p>When studies of women identified as low responders were compared with studies not restricted to women identified as low responders, the single study of low responders suggested a benefit in the intervention group, but there were too few studies to reach any firm conclusions and the test for subgroup differences was not statistically significant (Chi² = 3.33, df = 1 (P = 0.07), I² = 69.9%). <a href="./references#CD005070-fig-0008" title="">Analysis 1.2</a> </p> </section> <section id="CD005070-sec-0087"> <p><b>Subgroup analysis 1.3: Advanced age</b></p> <p>A single study was restricted to women of advanced age (<a href="./references#CD005070-bbs2-0035" title="VuongTNL , PhungHT , HoMT . Recombinant follicle‐stimulating hormone and recombinant luteinizing hormone versus recombinant follicle‐stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction2015;30(5):1188‐95. ">Vuong 2015</a>). There was no good evidence that the effects of the intervention differed between this study and the subgroup of studies not restricted to women of advanced age (test for subgroup differences: Chi² = 1.73, df = 1 (P = 0.19), I² = 42.3%), but there were too few studies to reach any conclusions. <a href="./references#CD005070-fig-0009" title="">Analysis 1.3</a> </p> </section> </section> <section id="CD005070-sec-0088"> <h6 class="title">2. Ovarian hyperstimulation syndrome</h6> <p>There was no evidence of a difference in ovarian hyperstimulation syndrome between ovarian stimulation with rLH combined with rFSH and ovarian stimulation with rFSH alone (OR 0.38, 95% CI 0.14 to 1.01; n = 2178; studies = 6; I<sup>2</sup> = 10%, low‐quality evidence) (<a href="./full#CD005070-tbl-0001">summary of findings Table for the main comparison</a>). The evidence suggests that if the risk of ovarian hyperstimulation syndrome following treatment with rFSH alone is 1%, the range of ovarian hyperstimulation syndrome varies between 0% and 1% using rLH combined with rFSH (<a href="./references#CD005070-fig-0010" title="">Analysis 1.4</a>). </p> <section id="CD005070-sec-0089"> <p><b>Subgroup analysis 2.1: Downregulating agent used</b></p> <p>There was no good evidence that the effects of the intervention differed by type of analogue (test for subgroup differences: Chi² = 2.15, df = 1 (P = 0.14), I² = 53.5%), but there were too few studies to reach any conclusions. <a href="./references#CD005070-fig-0010" title="">Analysis 1.4</a> </p> </section> <section id="CD005070-sec-0090"> <p><b>Subgroup analysis 2.2: Ovarian response</b></p> <p>No conclusions could be reached as there were no studies reporting ovarian hyperstimulation syndrome in women with low ovarian response. </p> </section> <section id="CD005070-sec-0091"> <p><b>Subgroup analysis 2.3: Advanced age</b></p> <p>No conclusions could be reached as only two studies reported ovarian hyperstimulation syndrome in women of advanced age (<a href="./references#CD005070-bbs2-0012" title="FabreguesF , IraolaA , CasalsG , CreusM , CarmonaF , BalaschJ . Evaluation of two doses of recombinant human luteinizing hormone supplementation in down‐regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2011;158:56‐61. ">Fabregues 2011</a>; <a href="./references#CD005070-bbs2-0013" title="FabreguesF , CreusM , PenarrubiaJ , ManauD , VanrellJA , BalaschJ . Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down‐regulated women of advanced reproductive age. Fertility and Sterility2006;85:925‐31. ">Fábreques 2006</a>), and there were no cases of ovarian hyperstimulation syndrome in either study. </p> </section> </section> </section> <section id="CD005070-sec-0092"> <h5 class="title">Secondary outcomes</h5> <section id="CD005070-sec-0093"> <h6 class="title">3. Ongoing pregnancy rate</h6> <p>The use of rLH combined with rFSH was associated with a higher ongoing pregnancy rate than rFSH alone (OR 1.20, 95% CI 1.01 to 1.42; n = 3129; studies = 19; I<sup>2</sup> = 2%, moderate‐quality evidence) (<a href="./full#CD005070-tbl-0001">summary of findings Table for the main comparison</a>). The evidence suggests that if the ongoing pregnancy rate following treatment with rFSH alone is 21%, the range of ongoing pregnancy rate varies between 21% and 27% using rLH combined with rFSH (<a href="./references#CD005070-fig-0011" title="">Analysis 1.5</a>). </p> <section id="CD005070-sec-0094"> <p><b>Subgroup analysis 3.1: Downregulating agent used</b></p> <p>Effects did not appear to differ by type of analogue (test for subgroup differences: Chi² = 0.75, df = 1 (P = 0.39), I² = 0%) (<a href="./references#CD005070-fig-0011" title="">Analysis 1.5</a>). </p> </section> <section id="CD005070-sec-0095"> <p><b>Subgroup analysis 3.2: Ovarian response</b></p> <p>When studies of women identified as low responders were compared with studies not restricted to women identified as low responders, the benefits of the intervention appeared to be stronger in women identified as low responders (OR 2.06, 95% CI 1.20 to 3.53, 79 women, 3 RCTs, I<sup>2</sup>=0%) and there was a significant difference between the subgroups (test for subgroup differences: Chi² = 4.33, df = 1 (P = 0.04), I² = 76.9%). This finding requires very cautious interpretation as the subgroup of low responders was very small (n = 79) and subgroup analyses should be regarded as exploratory, as they are not randomized comparisons (<a href="./references#CD005070-fig-0012" title="">Analysis 1.6</a>). </p> </section> <section id="CD005070-sec-0096"> <p><b>Subgroup analysis 3.3: Advanced age</b></p> <p>When studies restricted to women of advanced age were compared with studies not restricted by age, effects did not appear to differ between the two subgroups (Chi² = 0.46, df = 1 (P = 0.50), I² = 0%) (<a href="./references#CD005070-fig-0013" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD005070-sec-0097"> <h6 class="title">4. Clinical pregnancy rate</h6> <p>The use of rLH combined with rFSH was associated with a higher clinical pregnancy rate than rFSH alone (OR 1.18, 95% CI 1.03 to 1.34; n = 5071; studies = 23; I<sup>2</sup> = 33%). The evidence suggests that if the clinical pregnancy rate following treatment with rFSH alone is 24%, the range of the clinical pregnancy rate varies between 23% and 29% using rLH combined with rFSH (<a href="./references#CD005070-fig-0014" title="">Analysis 1.8</a>). One study described higher but no significant clinical pregnancy rates in patients treated with rLH combined with rFSH compared to rFSH alone, without showing absolute numbers (<a href="./references#CD005070-bbs2-0026" title="MohseniF , Dehgani FirouzabadiR , YariN , EtebaryS . Results of adding recombinant LH in normoresponder patients for assisted reproductive technology treatment: a prospective randomized control trial. International Journal of Fertility and Sterility2013;7:112. ">Mohseni 2013</a>). </p> </section> <section id="CD005070-sec-0098"> <h6 class="title">5. Miscarriage rate</h6> <p>The combination of rLH combined with rFSH was not associated with a difference in miscarriage rate compared to rFSH alone (OR 0.93, 95% CI 0.63 to 1.36; n = 1711; studies = 13; I<sup>2</sup> = 0%, moderate‐quality evidence) (<a href="./references#CD005070-fig-0015" title="">Analysis 1.9</a>; <a href="./full#CD005070-tbl-0001">summary of findings Table for the main comparison</a>). The evidence suggests that if the miscarriage rate following treatment with rFSH alone is 7%, the miscarriage rate following treatment with rLH combined with rFSH ranges between 4% and 9%. </p> </section> <section id="CD005070-sec-0099"> <h6 class="title">6. Cancellation due to low response</h6> <p>There was no evidence of a difference in cancellation rate due to low response between rLH combined with rFSH and rFSH alone (OR 0.77, 95% CI 0.54 to 1.10; n = 2251; studies = 11; I<sup>2</sup> = 16%) (<a href="./references#CD005070-fig-0016" title="">Analysis 1.10</a>). The evidence suggests that if the risk of cancellation due to low response following treatment with rFSH alone is 7%, the range of the cancellation rate due to low response varies between 4% and 7% using rLH combined with rFSH. </p> </section> <section id="CD005070-sec-0100"> <h6 class="title">7. Cancellation due to imminent ovarian hyperstimulation syndrome</h6> <p>Applying a fixed‐effect model to pool the data, cancellation rates due to imminent ovarian hyperstimulation syndrome were lower in women who received rLH combined with rFSH than in those who received rFSH alone (OR 0.60, 95% CI 0.40 to 0.89; n = 2976; studies = 8; I<sup>2</sup> = 60%) (<a href="./references#CD005070-fig-0017" title="">Analysis 1.11</a>). The evidence suggests that if the risk of cancellation due to imminent ovarian hyperstimulation syndrome following treatment with rFSH alone is 4%, the range of the cancellation due to imminent ovarian hyperstimulation syndrome varies between 2% and 4% using rLH combined with rFSH. However, heterogeneity was high (I<sup>2</sup>=60%) and applying a random‐effects model to pool the data resulted in an OR of 0.82 (95% CI 0.34 to 1.97). </p> </section> </section> </section> <section id="CD005070-sec-0101"> <h4 class="title">Investigation of publication bias</h4> <p>Visual scanning of funnel plots for clinical pregnancy (<a href="./references#CD005070-fig-0014" title="">Analysis 1.8</a>; <a href="#CD005070-fig-0005">Figure 5</a>), and cancellation due to low response (<a href="./references#CD005070-fig-0016" title="">Analysis 1.10</a>; <a href="#CD005070-fig-0006">Figure 6</a>), suggested a tendency towards publication bias, with smaller negative studies less likely to be included in the review. However, visual inspection of funnel plots for ongoing pregnancy (<a href="./references#CD005070-fig-0011" title="">Analysis 1.5</a>), and miscarriage (<a href="./references#CD005070-fig-0015" title="">Analysis 1.9</a>), did not reveal such a tendency towards publication bias in favour of larger studies with positive outcomes. </p> <div class="figure" id="CD005070-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 rLH plus rFSH versus rFSH alone for ovarian stimulation in IVF or ICSI treatment cycles, outcome: 1.8 Clinical pregnancy." data-id="CD005070-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 rLH plus rFSH versus rFSH alone for ovarian stimulation in IVF or ICSI treatment cycles, outcome: 1.8 Clinical pregnancy. </p> </div> </div> </div> <div class="figure" id="CD005070-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 rLH plus rFSH versus rFSH alone for OS in IVF or ICSI treatment cycles, outcome: 1.10 Adverse events (cancellation due to low response)." data-id="CD005070-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 rLH plus rFSH versus rFSH alone for OS in IVF or ICSI treatment cycles, outcome: 1.10 Adverse events (cancellation due to low response). </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005070-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005070-sec-0102"></div> <section id="CD005070-sec-0103"> <h3 class="title" id="CD005070-sec-0103">Summary of main results</h3> <p>There was no evidence of a difference in the live birth rate between women undergoing ovarian stimulation with recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) and women undergoing ovarian stimulation with rFSH alone, regardless of the type of downregulation. </p> <p>There was no evidence of a difference in the ovarian hyperstimulation syndrome rate or the miscarriage rate following ovarian stimulation with rLH combined with rFSH compared to rFSH alone in gonadotrophin‐releasing hormone (GnRH) analogue downregulated in‐vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) cycles. There was also no clear evidence of a difference between the groups in rates of cancellation due to low response or imminent OHSS. </p> <p>However the evidence suggested a higher ongoing pregnancy rate in women treated with rLH combined with rFSH compared to rFSH alone in GnRH analogue downregulated IVF/ICSI cycles. </p> <p>When studies of women identified as low responders were compared with studies not restricted to women identified as low responders, the ongoing pregnancy rate was higher in women identified as low responders. However the subgroup of low responders was very small (n = 79). This finding requires very cautious interpretation and should be regarded as exploratory. </p> </section> <section id="CD005070-sec-0104"> <h3 class="title" id="CD005070-sec-0104">Overall completeness and applicability of evidence</h3> <p>This Cochrane Review sought to evaluate the effectiveness of rLH combined with rFSH compared to rFSH alone for ovarian stimulation in downregulated IVF or ICSI cycles. We included 36 RCTs, totaling 8125 women. The sample sizes in the studies ranged between 30 and 999. Only four of the included studies, totalling 499 women had data on the primary outcome measure, live birth rate. To be able to show a difference of 5% compared to a standard live birth rate of 17%, one would require to include at least 1970 couples. Six of the included studies had data on the ovarian hyperstimulation syndrome rate. The evidence is generally applicable to women undergoing the conventional stimulation regimens in GnRH analogue downregulated IVF/ICSI cycles. </p> <p>The sample size for the subgroup analysis in women with poor ovarian response and in women of advanced age was small, therefore there is insufficient evidence to make a conclusive judgement of any beneficial effect of rLH combined with rFSH in IVF or ICSI cycles compared to rFSH alone in these women. </p> </section> <section id="CD005070-sec-0105"> <h3 class="title" id="CD005070-sec-0105">Quality of the evidence</h3> <p>The overall quality of the evidence was very low for live birth, low for ovarian hyperstimulation syndrome and moderate for ongoing pregnancy and miscarriage. The main limitations in the evidence for the primary outcome live birth rate and for the secondary outcome miscarriage was imprecision, due to the small amount of data. We downgraded the quality of evidence of ovarian hyperstimulation syndrome and ongoing pregnancy because there was risk of bias associated with poor reporting of study methods. </p> <p>Only seven of the 36 studies (19%) clearly stated that they were funded by government or research institutes. Six (17%) were funded by pharmaceutical companies and the rest (64%) did not state their source of funding. </p> </section> <section id="CD005070-sec-0106"> <h3 class="title" id="CD005070-sec-0106">Potential biases in the review process</h3> <p>The review authors minimised the risk of bias by conducting a search that was systematic and thorough and by having two review authors independently perform the data extraction, risk of bias assessment, and GRADE evaluation. </p> </section> <section id="CD005070-sec-0107"> <h3 class="title" id="CD005070-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>Our results are in agreement with those of a previous systematic review and meta‐analysis, comparing rLH combined with rFSH to rFSH alone in GnRH antagonist in downregulated IVF/ICSI cycles (<a href="./references#CD005070-bbs2-0073" title="XiongY , BuZ , DaiW , ZhangM , BaoX , SunY . Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta‐analysis. Reproductive Biology and Endocrinology2014;12:109. ">Xiong 2014</a>). This review identified four of the 11 studies that we included, and included one other study (<a href="./references#CD005070-bbs2-0054" title="SauerMV , ThorntonMH2nd , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>). We excluded <a href="./references#CD005070-bbs2-0054" title="SauerMV , ThorntonMH2nd , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>, since they randomized between using GnRH agonists (leuprolide) combined with rFSH versus using GnRH antagonists (cetrorelix) with or without rLH. </p> <p>Our results were also in line with the results of another systematic review and meta‐analysis that compared the combination of rLH and rFSH to rFSH alone in women of advanced reproductive age undergoing IVF/ICSI (<a href="./references#CD005070-bbs2-0064" title="HillMJ , LevensED , LevyG , RyanME , CsokmayJM , DeCherneyAH , et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta‐analysis. Fertility and Sterility2012;97(5):1108‐14. ">Hill 2012</a>). This review identified the same studies that we identified. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005070-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005070-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005070-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005070-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 rLH plus rFSH versus rFSH alone for OS in IVF or ICSI treatment cycles, outcome: 1.1 Live birth rate." data-id="CD005070-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 rLH plus rFSH versus rFSH alone for OS in IVF or ICSI treatment cycles, outcome: 1.1 Live birth rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 rLH plus rFSH versus rFSH alone for ovarian stimulation in IVF or ICSI treatment cycles, outcome: 1.8 Clinical pregnancy." data-id="CD005070-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 rLH plus rFSH versus rFSH alone for ovarian stimulation in IVF or ICSI treatment cycles, outcome: 1.8 Clinical pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 rLH plus rFSH versus rFSH alone for OS in IVF or ICSI treatment cycles, outcome: 1.10 Adverse events (cancellation due to low response)." data-id="CD005070-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 rLH plus rFSH versus rFSH alone for OS in IVF or ICSI treatment cycles, outcome: 1.10 Adverse events (cancellation due to low response). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 1 Live birth rate." data-id="CD005070-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 1 Live birth rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 2 Subgroup analysis: Live birth by ovarian response." data-id="CD005070-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 2 Subgroup analysis: Live birth by ovarian response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 3 Subgroup analysis: Live birth by advanced age." data-id="CD005070-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 3 Subgroup analysis: Live birth by advanced age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 4 OHSS." data-id="CD005070-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 4 OHSS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 5 Ongoing pregnancy." data-id="CD005070-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 5 Ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 6 Subgroup analysis: ongoing pregnancy by ovarian response." data-id="CD005070-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 6 Subgroup analysis: ongoing pregnancy by ovarian response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 7 Subgroup analysis: ongoing pregnancy by advanced age." data-id="CD005070-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 7 Subgroup analysis: ongoing pregnancy by advanced age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 8 Clinical pregnancy." data-id="CD005070-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 8 Clinical pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 9 Miscarriage rate." data-id="CD005070-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 9 Miscarriage rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 10 Adverse events (cancellation due to low response)." data-id="CD005070-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 10 Adverse events (cancellation due to low response). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005070-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/urn:x-wiley:14651858:media:CD005070:CD005070-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_t/tCD005070-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 11 Adverse events (cancellation due to imminent OHSS)." data-id="CD005070-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles, Outcome 11 Adverse events (cancellation due to imminent OHSS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/media/CDSR/CD005070/image_n/nCD005070-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005070-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) versus rFSH alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women undergoing ovarian stimulation in IVF or ICSI treatment cycles<br/> <b>Settings:</b> assisted reproduction clinics<br/> <b>Intervention:</b> rLH combined with rFSH<br/> <b>Comparison:</b> rFSH alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> rFSH alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> rLH plus rFSH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>173 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> <br/> (151 to 302) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b> <br/> (0.85 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS incidence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (2 to 13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.38</b> <br/> (0.14 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2178<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ongoing pregnancy rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>206 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> <br/> (207 to 269) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.20</b> <br/> (1.01 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3129<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Miscarriage rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>65 per 1000</b> </p> <p>(45 to 93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.93</b> </p> <p>(0.63 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1711</p> <p>(13 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cancellation rate for low response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>52 per 1000</p> <p>(37 to 73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.77</p> <p>(0.54 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2251</p> <p>(11 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cancellation rate for imminent OHSS</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>27 per 1000</p> <p>(18 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.60</p> <p>(0.40 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2976</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>very low</b><sup>2,4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IVF</b> : in‐vitro fertilisation<b>; OHSS</b> : ovarian hyperstimulation syndrome; <b>OR:</b> Odds ratio; <b>rFSH:</b> recombinant follicle‐stimulating hormone;<b>rLH:</b> recombinant luteinizing hormone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High‐quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate‐quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low‐quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low‐quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to imprecision: effect estimate with wide confidence interval (wider than the interval 0.75 to 1.25) or low event rate.<br/> <sup>2</sup> Downgraded one level due to the presence of serious risk of bias in certain domains such as random sequence generation and allocation concealment.<br/> <sup>3</sup>Downgraded two levels due to very serious imprecision with wide confidence interval (wider than the interval 0.75 to 1.25) and very low event rate. </p> <p><sup>4</sup> Downgraded one level due to inconsistency (I<sup>2</sup> &gt;50%) </p> <p><sup>5</sup>Downgraded one level due to imprecision: findings are sensitive to choice of statistical model and are not statistically significant with use of a random effects model (OR 0.82, 95% CI 0.34 to 1.97) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) versus rFSH alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/full#CD005070-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005070-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.85, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 GnRH agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.95, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 GnRH antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.48, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Subgroup analysis: Live birth by ovarian response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.85, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies restricted to women with low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.33 [1.03, 84.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Studies not restricted to women with low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.72, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Subgroup analysis: Live birth by advanced age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.85, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Studies restricted to women of advanced age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.48, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Studies not restricted to women of advanced age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.95, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.14, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 GnRH agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.03, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 GnRH antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.21, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.01, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 GnRH agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.02, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 GnRH antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.82, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Subgroup analysis: ongoing pregnancy by ovarian response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.01, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Studies restricted to women with low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.20, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Studies not restricted to women with low response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.94, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Subgroup analysis: ongoing pregnancy by advanced age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.01, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Studies restricted to women of advanced age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.84, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Studies not restricted to women of advanced age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.00, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.03, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.63, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events (cancellation due to low response) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.54, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events (cancellation due to imminent OHSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.40, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) compared to rFSH alone for ovarian stimulation in in‐vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005070.pub3/references#CD005070-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005070.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005070-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005070-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005070-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="pt#CD005070-note-0001">Português</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005070\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005070\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005070\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005070\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005070\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005070.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005070.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005070.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005070.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005070.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717034805"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005070.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717034808"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005070.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dae0f49bef3f1',t:'MTc0MDcxNzAzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 